Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
23,900 | 2021-09-23 00:00:00 UTC | XLV, ABBV, LLY, BMY: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/xlv-abbv-lly-bmy%3A-large-outflows-detected-at-etf-2021-09-23 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $526.3 million dollar outflow -- that's a 1.6% decrease week over week (from 251,370,000 to 247,3... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.3%, Eli Lilly (Symbol: LLY) is up about 1.9%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.3%, Eli Lilly (Symbol: LLY) is up about 1.9%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 1.4%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price p... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.3%, Eli Lilly (Symbol: LLY) is up about 1.9%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.3%, Eli Lilly (Symbol: LLY) is up about 1.9%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... |
23,901 | 2021-09-23 00:00:00 UTC | November 5th Options Now Available For AbbVie | ABBV | https://www.nasdaq.com/articles/november-5th-options-now-available-for-abbvie-2021-09-23 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the November 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new November 5th contracts and identified one put and one call contract of particular interest.
The put cont... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $120.00 strike highlighted in red: Considering the fact that the $120.00 strike represents an approximate 11% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the po... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $104.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $120.00 strike price has a current bid of 30 cents. Below is a chart showing ... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new November 5th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $120.00 strike highlighted in red: Consid... |
23,902 | 2021-09-23 00:00:00 UTC | 3 Relatively Safe Pharma Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-relatively-safe-pharma-stocks-you-can-buy-right-now-2021-09-23 | null | null | Volatility has been on full display in the stock market this week. The wild swings are enough to cause many investors to look for safe havens to park their hard-earned cash. One option to consider is buying the stocks of drugmakers that generate dependable cash flow.
We asked three Motley Fool contributors to identify ... | Here's why those chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). AbbVie: a rock-solid pharma giant at an attractive valuation Prosper Junior Bakiny (AbbVie): Investors looking for safety in this volatile market can't go wrong with AbbVie. That's why AbbVie can continue gene... | Here's why those chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). AbbVie: a rock-solid pharma giant at an attractive valuation Prosper Junior Bakiny (AbbVie): Investors looking for safety in this volatile market can't go wrong with AbbVie. That's why AbbVie can continue gene... | Here's why those chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). AbbVie: a rock-solid pharma giant at an attractive valuation Prosper Junior Bakiny (AbbVie): Investors looking for safety in this volatile market can't go wrong with AbbVie. That's why AbbVie can continue gene... | Here's why those chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). AbbVie: a rock-solid pharma giant at an attractive valuation Prosper Junior Bakiny (AbbVie): Investors looking for safety in this volatile market can't go wrong with AbbVie. That's why AbbVie can continue gene... |
23,903 | 2021-09-23 00:00:00 UTC | Should You Buy Merck Stock At $72? | ABBV | https://www.nasdaq.com/articles/should-you-buy-merck-stock-at-%2472-2021-09-23 | null | null | The stock price of Merck (NYSE: MRK) reached its all-time high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, and it currently trades at levels of around $72. We believe that MRK stock is undervalued at its current levels, and investors can use the recent di... | There has been a rise in pet ownership during the pandemic and this has resulted in an increased demand for animal health pharmaceuticals products at large, including those offered by Merck. Merck’s cash-cow – Keytruda – continues to gain share in several markets given its approval in multiple indications, including, l... | The revenue growth can largely be attributed to market share gains for its mega-blockbuster drug – Keytruda – approved for multiple types of cancer treatments. As such, on a per share basis, Merck’s earnings surged 150% to $2.20 for the last twelve month period, compared to $0.88 in 2017. Despite a large EPS growth ove... | The growth in Merck’s earnings was partly offset by a decline in its P/E multiple, resulting in slower stock appreciation. Despite a large EPS growth over the recent years, Merck’s P/E multiple has contracted 49% to 33x currently, compared to levels of 64x seen in 2017, and we believe that the multiple will likely exp... | MRK stock is down more than 15% over the last year or so, despite revenue increasing 6% over the same period. Despite a large EPS growth over the recent years, Merck’s P/E multiple has contracted 49% to 33x currently, compared to levels of 64x seen in 2017, and we believe that the multiple will likely expand over the c... |
23,904 | 2021-09-22 00:00:00 UTC | 3 Cheap Healthcare Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-cheap-healthcare-stocks-to-buy-right-now-2021-09-22 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The Covid-19 pandemic brought a renewed interest into the healthcare sector, and with the surging Delta variant raging across the country, that interest isn’t expected to dissipate anytime soon. Due to that attention, many healthcare stocks have reached sky... | Empliciti, an IgG1 monoclonal antibody medication co-developed with AbbVie (NYSE:ABBV), also contributes to top-line growth. Plus, its person-to-person affiliate marketing channel has created more brand awareness and helped the firm acquire customers at a higher rate. 7 Buffett Stocks Trading at a Steep Discount You Ne... | Empliciti, an IgG1 monoclonal antibody medication co-developed with AbbVie (NYSE:ABBV), also contributes to top-line growth. Ironwood Pharmaceuticals (NASDAQ:IRWD), Nu Skin Enterprises (NYSE:NUS) Bristol-Myers Squibb (NYSE:BMY) Healthcare Stocks: Ironwood Pharmaceuticals, Inc. (IRWD) Source: Shutterstock IRWD is a spec... | Empliciti, an IgG1 monoclonal antibody medication co-developed with AbbVie (NYSE:ABBV), also contributes to top-line growth. That’s why investors should consider healthcare stocks with an overall grade of “buy” and a Value Grade of A in our POWR Ratings system. Ironwood Pharmaceuticals (NASDAQ:IRWD), Nu Skin Enterprise... | Empliciti, an IgG1 monoclonal antibody medication co-developed with AbbVie (NYSE:ABBV), also contributes to top-line growth. 21 in the Medical – Pharmaceuticals industry. 14 in the Medical – Pharmaceuticals industry. |
23,905 | 2021-09-20 00:00:00 UTC | AbbVie Seeks Approval For SKYRIZI Based On Data From Three Phase 3 Studies | ABBV | https://www.nasdaq.com/articles/abbvie-seeks-approval-for-skyrizi-based-on-data-from-three-phase-3-studies-2021-09-20 | null | null | (RTTNews) - AbbVie (ABBV) has submitted an application to the FDA seeking approval for risankizumab-rzaa or SKYRIZI, for the treatment of patients 16 years and older with moderate to severe Crohn's disease. The submission is supported by data from three phase 3 studies - ADVANCE, MOTIVATE and FORTIFY.
Crohn's disease i... | (RTTNews) - AbbVie (ABBV) has submitted an application to the FDA seeking approval for risankizumab-rzaa or SKYRIZI, for the treatment of patients 16 years and older with moderate to severe Crohn's disease. SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and c... | (RTTNews) - AbbVie (ABBV) has submitted an application to the FDA seeking approval for risankizumab-rzaa or SKYRIZI, for the treatment of patients 16 years and older with moderate to severe Crohn's disease. SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and c... | (RTTNews) - AbbVie (ABBV) has submitted an application to the FDA seeking approval for risankizumab-rzaa or SKYRIZI, for the treatment of patients 16 years and older with moderate to severe Crohn's disease. SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and c... | (RTTNews) - AbbVie (ABBV) has submitted an application to the FDA seeking approval for risankizumab-rzaa or SKYRIZI, for the treatment of patients 16 years and older with moderate to severe Crohn's disease. SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and c... |
23,906 | 2021-09-20 00:00:00 UTC | Best Dividend Stocks In 2021? 4 To Watch This Week | ABBV | https://www.nasdaq.com/articles/best-dividend-stocks-in-2021-4-to-watch-this-week-2021-09-20 | null | null | 4 Dividend Stocks Worth Checking Out In A Down Market
As we begin another trading week, dividend stocks are once again at the forefront for investors. For the most part, this could be thanks to various factors, international and domestic, that are weighing on the stock market today. To begin, the market appears to be r... | “While there have been advancements in care, many people with Crohn’s disease do not achieve lasting remission,” said Tom Hudson, senior vice president of research and development, chief scientific officer, AbbVie. Top Dividend Stocks To Buy [Or Sell] This Week Apple Inc. (NASDAQ: AAPL) 3M Inc. (NYSE: MMM) AbbVie Inc. ... | Top Dividend Stocks To Buy [Or Sell] This Week Apple Inc. (NASDAQ: AAPL) 3M Inc. (NYSE: MMM) AbbVie Inc. (NYSE: ABBV) Microsoft Corporation (NASDAQ: MSFT) Apple Inc. First up, we have Apple, a multinational technology company that manufactures and sells its premium line of tech products. 5 To Watch AbbVie Inc. Followin... | Top Dividend Stocks To Buy [Or Sell] This Week Apple Inc. (NASDAQ: AAPL) 3M Inc. (NYSE: MMM) AbbVie Inc. (NYSE: ABBV) Microsoft Corporation (NASDAQ: MSFT) Apple Inc. First up, we have Apple, a multinational technology company that manufactures and sells its premium line of tech products. 5 To Watch AbbVie Inc. Followin... | Top Dividend Stocks To Buy [Or Sell] This Week Apple Inc. (NASDAQ: AAPL) 3M Inc. (NYSE: MMM) AbbVie Inc. (NYSE: ABBV) Microsoft Corporation (NASDAQ: MSFT) Apple Inc. First up, we have Apple, a multinational technology company that manufactures and sells its premium line of tech products. 5 To Watch AbbVie Inc. Followin... |
23,907 | 2021-09-20 00:00:00 UTC | AbbVie Is Worth 28% More Based on Impressive Dividends | ABBV | https://www.nasdaq.com/articles/abbvie-is-worth-28-more-based-on-impressive-dividends-2021-09-20 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie (NYSE:ABBV) stock is cheap and has a very attractive prospective dividend yield. In addition, this pharmaceutical company’s growth prospects are high. As a result, ABBV stock is likely worth significantly more than the price of $107.73 as of Sept. 17... | The reason behind the move is that the FDA now requires AbbVie’s RINVOQ, one of its blockbuster arthritis drugs, to have a heart-related event risk label put on the dispensing bottles. What to Do With ABBV Stock AbbVie is likely to see good news with a higher dividend per share declaration next month. InvestorPlace - S... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is cheap and has a very attractive prospective dividend yield. For example, in the past four years, ABBV stock has had an average dividend yield of 4.43%, much lower than today’s 5.3% dividend yield using the forecast higher DPS of ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is cheap and has a very attractive prospective dividend yield. Valuing ABBV Stock with Dividend Yields and P/E One way to value the stock is to compare its present dividend yield to its historical yield. For example, in the past fou... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is cheap and has a very attractive prospective dividend yield. For example, in the past four years, ABBV stock has had an average dividend yield of 4.43%, much lower than today’s 5.3% dividend yield using the forecast higher DPS of ... |
23,908 | 2021-09-19 00:00:00 UTC | Is AbbVie a Bad News Buy? | ABBV | https://www.nasdaq.com/articles/is-abbvie-a-bad-news-buy-2021-09-19 | null | null | The U.S. Food and Drug Administration recently announced restrictions on JAK inhibitors that hurt AbbVie's (NYSE: ABBV) prospects for autoimmune disease drug Rinvoq. AbbVie stock sank more than 10% after the FDA's decision. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and ... | The FDA has been reviewing the data, and it put off making decisions on multiple JAK inhibitors, ones from Pfizer and AbbVie and then one that's being developed by Eli Lilly (NYSE: LLY) and Incyte (NASDAQ: INCY), and that's for various different indications. Rinvoq is a lot more important to AbbVie's future than Xeljan... | The U.S. Food and Drug Administration recently announced restrictions on JAK inhibitors that hurt AbbVie's (NYSE: ABBV) prospects for autoimmune disease drug Rinvoq. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie stock is now a ... | In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie stock is now a bad news buy. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! The FDA has been reviewi... | In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie stock is now a bad news buy. The FDA has been reviewing the data, and it put off making decisions on multiple JAK inhibitors, ones from Pfizer and AbbVie and then one that's being d... |
23,909 | 2021-09-18 00:00:00 UTC | AbbVie's Pain Is Sanofi's and Regeneron's Gain | ABBV | https://www.nasdaq.com/articles/abbvies-pain-is-sanofis-and-regenerons-gain-2021-09-18 | null | null | The U.S. Food and Drug Administration recently announced that it's requiring a warning about potential health issues linked to JAK inhibitors. The agency is also restricting the use of the drugs to patients who were unsuccessfully treated with at least one TNF inhibitor.
This decision especially hurts AbbVie (NYSE: ABB... | In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss how the FDA decision that's causing pain for AbbVie should help Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN). This decision especially hurts AbbVie (NYSE: ABBV). See the 10 stocks *Stock Advisor ret... | In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss how the FDA decision that's causing pain for AbbVie should help Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN). See the 10 stocks *Stock Advisor returns as of August 9, 2021 Keith Speights: Now this F... | In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss how the FDA decision that's causing pain for AbbVie should help Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN). See the 10 stocks *Stock Advisor returns as of August 9, 2021 Keith Speights: Now this F... | In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss how the FDA decision that's causing pain for AbbVie should help Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN). See the 10 stocks *Stock Advisor returns as of August 9, 2021 Keith Speights: Now this F... |
23,910 | 2021-09-17 00:00:00 UTC | Why BeiGene's Shares Jumped on Friday | ABBV | https://www.nasdaq.com/articles/why-beigenes-shares-jumped-on-friday-2021-09-17 | null | null | What happened
BeiGene (NASDAQ: BGNE), a Chinese pharmaceutical company, saw its shares rise more than 10% in early trading on Friday. The stock, which closed at $385.24 on Thursday, opened Friday at $422 a share, climbing as high as $426.56 in mid-morning trading. The stock is up more than 55% year to date.
IMAGE SOURC... | If Brukinsa can show superior efficacy and safety to Imbruvica, the market's top-selling BTK inhibitor, that would be a big deal: AbbVie made $5.3 billion last year in revenue from Imbruvica. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Jim Halley owns shares of AbbVie. On Wednesday, BeiGene said that ... | See the 10 stocks *Stock Advisor returns as of August 9, 2021 Jim Halley owns shares of AbbVie. If Brukinsa can show superior efficacy and safety to Imbruvica, the market's top-selling BTK inhibitor, that would be a big deal: AbbVie made $5.3 billion last year in revenue from Imbruvica. It is the third FDA approval for... | If Brukinsa can show superior efficacy and safety to Imbruvica, the market's top-selling BTK inhibitor, that would be a big deal: AbbVie made $5.3 billion last year in revenue from Imbruvica. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Jim Halley owns shares of AbbVie. On Wednesday, BeiGene said that ... | If Brukinsa can show superior efficacy and safety to Imbruvica, the market's top-selling BTK inhibitor, that would be a big deal: AbbVie made $5.3 billion last year in revenue from Imbruvica. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Jim Halley owns shares of AbbVie. BeiGene, a biotech company, repo... |
23,911 | 2021-09-17 00:00:00 UTC | What's Next For Merck Stock After A 5% Fall In A Week? | ABBV | https://www.nasdaq.com/articles/whats-next-for-merck-stock-after-a-5-fall-in-a-week-2021-09-17 | null | null | The stock price of Merck (NYSE: MRK) reached its all-time high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, before a recent sell-off in pharmaceutical stocks resulted in MRK falling to $72 levels currently. MRK stock is down over 5% in the last five tradin... | Even before the recent fall, MRK stock underperformed its peers, due to rising concerns of slowing sales for some of its drugs, such as, Januvia and Janumet, along with the impact of the Covid-19 pandemic on its vaccines, including Gardasil. However, the recent decline can be attributed to rising concerns over the Bide... | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for MRK stock average around 4.1% in the next one-month (twenty-one trading days) period after experiencing a 5.1% drop over the previous week (five trading days), implying t... | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for MRK stock average around 4.1% in the next one-month (twenty-one trading days) period after experiencing a 5.1% drop over the previous week (five trading days), implying t... | You can test the chance of recovery over different time intervals of a quarter, month, or even just 1 day! MACHINE LEARNING ENGINE – try it yourself: IF MRK stock moved by -5% over five trading days, THEN over the next twenty-one trading days MRK stock moves an average of 4%, with a strong 77% probability of a positive... |
23,912 | 2021-09-16 00:00:00 UTC | AbbVie Files For FDA And EMA Approval Of Upadacitinib For Ulcerative Colitis | ABBV | https://www.nasdaq.com/articles/abbvie-files-for-fda-and-ema-approval-of-upadacitinib-for-ulcerative-colitis-2021-09-16 | null | null | (RTTNews) - AbbVie (ABBV), on Thursday, announced that it has submitted applications to the FDA and European Medicines Agency, pursuing expanded approval for Upadacitinib.
The company is seeking approval for Upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for the treatment of adults with mo... | (RTTNews) - AbbVie (ABBV), on Thursday, announced that it has submitted applications to the FDA and European Medicines Agency, pursuing expanded approval for Upadacitinib. Commenting on the regulatory filings, Tom Hudson, senior vice president of research and development, chief scientific officer, AbbVie, said, "Upadac... | (RTTNews) - AbbVie (ABBV), on Thursday, announced that it has submitted applications to the FDA and European Medicines Agency, pursuing expanded approval for Upadacitinib. Commenting on the regulatory filings, Tom Hudson, senior vice president of research and development, chief scientific officer, AbbVie, said, "Upadac... | (RTTNews) - AbbVie (ABBV), on Thursday, announced that it has submitted applications to the FDA and European Medicines Agency, pursuing expanded approval for Upadacitinib. Commenting on the regulatory filings, Tom Hudson, senior vice president of research and development, chief scientific officer, AbbVie, said, "Upadac... | (RTTNews) - AbbVie (ABBV), on Thursday, announced that it has submitted applications to the FDA and European Medicines Agency, pursuing expanded approval for Upadacitinib. Commenting on the regulatory filings, Tom Hudson, senior vice president of research and development, chief scientific officer, AbbVie, said, "Upadac... |
23,913 | 2021-09-16 00:00:00 UTC | 2 Embarrassingly Cheap Dividend Stocks to Buy | ABBV | https://www.nasdaq.com/articles/2-embarrassingly-cheap-dividend-stocks-to-buy-2021-09-16 | null | null | Benjamin Graham, the father of value investing and mentor to Warren Buffett, explained that in the short term, the market is a "voting machine" and stocks are judged by their popularity with investors. But in the long term, he continued, the market is a "weighing machine" -- meaning a stock's fundamentals are what matt... | AbbVie is trading at less than nine times this year's anticipated adjusted EPS, which leaves value investors with an ample margin of safety while collecting a whopper of a yield. A well-prepared pharma stock The next value stock on our list is the pharma stock AbbVie (NYSE: ABBV). At this point, it's well known to the ... | In addition to AbbVie's intact operating fundamentals ahead of Humira's U.S. patent expiration, the current 4.8% dividend yield appears to have a big buffer built into it. A well-prepared pharma stock The next value stock on our list is the pharma stock AbbVie (NYSE: ABBV). At this point, it's well known to the investi... | A well-prepared pharma stock The next value stock on our list is the pharma stock AbbVie (NYSE: ABBV). Based on AbbVie's forecasted adjusted earnings per share (EPS) of $12.52 to $12.62 and dividends per share of $5.20 for this year, its payout ratio will be around 41% for the year. At this point, it's well known to th... | Based on AbbVie's forecasted adjusted earnings per share (EPS) of $12.52 to $12.62 and dividends per share of $5.20 for this year, its payout ratio will be around 41% for the year. A well-prepared pharma stock The next value stock on our list is the pharma stock AbbVie (NYSE: ABBV). At this point, it's well known to th... |
23,914 | 2021-09-16 00:00:00 UTC | ANALYSIS-China's biotech sector comes of age with big licensing deals, global ambitions | ABBV | https://www.nasdaq.com/articles/analysis-chinas-biotech-sector-comes-of-age-with-big-licensing-deals-global-ambitions-0 | null | null | By Farah Master
HONG KONG, Sept 16 (Reuters) - If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing deal RemeGen Co Ltd 9995.HK struck last month with Seattle-based Seagen Inc SGEN.O fits the bill.
The agreement to co-develop cancer treatments using a Re... | AbbVie ABBV.N has also partnered with I-Mab IMAB.O to co-develop a monoclonal antibody for several types of cancer in a deal worth up to $1.9 billion. By Farah Master HONG KONG, Sept 16 (Reuters) - If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing dea... | AbbVie ABBV.N has also partnered with I-Mab IMAB.O to co-develop a monoclonal antibody for several types of cancer in a deal worth up to $1.9 billion. By Farah Master HONG KONG, Sept 16 (Reuters) - If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing dea... | AbbVie ABBV.N has also partnered with I-Mab IMAB.O to co-develop a monoclonal antibody for several types of cancer in a deal worth up to $1.9 billion. The agreement to co-develop cancer treatments using a RemeGen antibody drug conjugate is regarded as one of the biggest of its kind between a Chinese biotech and a Weste... | AbbVie ABBV.N has also partnered with I-Mab IMAB.O to co-develop a monoclonal antibody for several types of cancer in a deal worth up to $1.9 billion. The agreement to co-develop cancer treatments using a RemeGen antibody drug conjugate is regarded as one of the biggest of its kind between a Chinese biotech and a Weste... |
23,915 | 2021-09-15 00:00:00 UTC | ANALYSIS-China's biotech sector comes of age with big licensing deals, global ambitions | ABBV | https://www.nasdaq.com/articles/analysis-chinas-biotech-sector-comes-of-age-with-big-licensing-deals-global-ambitions-2021 | null | null | By Farah Master
HONG KONG, Sept 16 (Reuters) - If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing deal RemeGen Co Ltd 9995.HK struck last month with Seattle-based Seagen Inc SGEN.O fits the bill.
The agreement to co-develop cancer treatments using a Re... | AbbVie ABBV.N has also partnered with I-Mab IMAB.O to co-develop a monoclonal antibody for several types of cancer in a deal worth up to $1.9 billion. By Farah Master HONG KONG, Sept 16 (Reuters) - If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing dea... | AbbVie ABBV.N has also partnered with I-Mab IMAB.O to co-develop a monoclonal antibody for several types of cancer in a deal worth up to $1.9 billion. By Farah Master HONG KONG, Sept 16 (Reuters) - If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing dea... | AbbVie ABBV.N has also partnered with I-Mab IMAB.O to co-develop a monoclonal antibody for several types of cancer in a deal worth up to $1.9 billion. The agreement to co-develop cancer treatments using a RemeGen antibody drug conjugate is regarded as one of the biggest of its kind between a Chinese biotech and a Weste... | AbbVie ABBV.N has also partnered with I-Mab IMAB.O to co-develop a monoclonal antibody for several types of cancer in a deal worth up to $1.9 billion. The agreement to co-develop cancer treatments using a RemeGen antibody drug conjugate is regarded as one of the biggest of its kind between a Chinese biotech and a Weste... |
23,916 | 2021-09-15 00:00:00 UTC | 5 Biopharmaceutical Stocks To Watch Amidst Global Economic Growth Concerns | ABBV | https://www.nasdaq.com/articles/5-biopharmaceutical-stocks-to-watch-amidst-global-economic-growth-concerns-2021-09-15 | null | null | Are These Top Biopharmaceutical Stocks In Your September 2021 Watchlist?
As stocks continue to sell off this September, biopharmaceutical stocks continue to gain traction in thestock market today Aside from investor fears over broad-based selling, new economic data from China is also weighing in on the stock market now... | Top Biopharmaceutical Stocks To Watch Right Now Adagio Therapeutics Inc. (NASDAQ: ADGI) Pfizer Inc. (NYSE: PFE) Vera Therapeutics Inc. (NASDAQ: VERA) Eli Lilly and Company (NYSE: LLY) AbbVie Inc. (NYSE: ABBV) Adagio Therapeutics Inc. Adagio Therapeutics is a clinical-stage biopharmaceutical company that develops and co... | Top Biopharmaceutical Stocks To Watch Right Now Adagio Therapeutics Inc. (NASDAQ: ADGI) Pfizer Inc. (NYSE: PFE) Vera Therapeutics Inc. (NASDAQ: VERA) Eli Lilly and Company (NYSE: LLY) AbbVie Inc. (NYSE: ABBV) Adagio Therapeutics Inc. Adagio Therapeutics is a clinical-stage biopharmaceutical company that develops and co... | Top Biopharmaceutical Stocks To Watch Right Now Adagio Therapeutics Inc. (NASDAQ: ADGI) Pfizer Inc. (NYSE: PFE) Vera Therapeutics Inc. (NASDAQ: VERA) Eli Lilly and Company (NYSE: LLY) AbbVie Inc. (NYSE: ABBV) Adagio Therapeutics Inc. Adagio Therapeutics is a clinical-stage biopharmaceutical company that develops and co... | Top Biopharmaceutical Stocks To Watch Right Now Adagio Therapeutics Inc. (NASDAQ: ADGI) Pfizer Inc. (NYSE: PFE) Vera Therapeutics Inc. (NASDAQ: VERA) Eli Lilly and Company (NYSE: LLY) AbbVie Inc. (NYSE: ABBV) Adagio Therapeutics Inc. Adagio Therapeutics is a clinical-stage biopharmaceutical company that develops and co... |
23,917 | 2021-09-15 00:00:00 UTC | Is AbbVie's 4.9% Dividend Yield Safe? | ABBV | https://www.nasdaq.com/articles/is-abbvies-4.9-dividend-yield-safe-2021-09-15 | null | null | Drugmaker AbbVie (NYSE: ABBV) pays a relatively high yield of 4.9%. That's well above the average S&P 500 stock, which offers just 1.3% in recurring income. On a $10,000 investment, that's $360 more in annual dividend income you could earn through AbbVie. Multiply that by several years of owning the stock, plus the reg... | AbbVie's yield went up a bit earlier this month after investors dumped the stock, which fell by more than 7% on Sept. 1 after the U.S. Food and Drug Administration said it would require the company to add a warning label to its arthritis medication, Rinvoq. And I'd argue that not only does the dividend look incredibly ... | The company's business is solid without Rinvoq Although investors were quick to sell their shares of AbbVie, the move looks to be unjustified; Rinvoq has generated just $681 million in revenue for the company over the first six months of 2021. Even with a possible loss in revenue from Humira and softer-than-expected nu... | AbbVie's yield went up a bit earlier this month after investors dumped the stock, which fell by more than 7% on Sept. 1 after the U.S. Food and Drug Administration said it would require the company to add a warning label to its arthritis medication, Rinvoq. The company's business is solid without Rinvoq Although invest... | On a $10,000 investment, that's $360 more in annual dividend income you could earn through AbbVie. Even with a possible loss in revenue from Humira and softer-than-expected numbers from Rinvoq in the future, AbbVie has a significant buffer between its annual payout and adjusted earnings, which should alleviate any fear... |
23,918 | 2021-09-15 00:00:00 UTC | AbbVie To Present At Morgan Stanley Virtual Global Healthcare Conference; Webcast At 10:15 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-to-present-at-morgan-stanley-virtual-global-healthcare-conference-webcast-at-10%3A15 | null | null | (RTTNews) - AbbVie (ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference.
The event is scheduled to begin at 10:15 AM ET on September 15, 2021.
To access the live webcast, log on to http://investors.abbvie.com
The views and opinions expressed herein are the views and opinions of... | (RTTNews) - AbbVie (ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference. To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The e... | (RTTNews) - AbbVie (ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference. To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The e... | (RTTNews) - AbbVie (ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference. To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The e... | (RTTNews) - AbbVie (ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference. To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The e... |
23,919 | 2021-09-13 00:00:00 UTC | US STOCKS-Energy, financials help Wall Street rise from bruising week | ABBV | https://www.nasdaq.com/articles/us-stocks-energy-financials-help-wall-street-rise-from-bruising-week-2021-09-13 | null | null | By Ambar Warrick and Devik Jain
Sept 13 (Reuters) - Wall Street indexes on Monday rose from their worst week in several months, with economically sensitive stocks leading gains as focus turned to potential changes to corporate tax and monetary policy.
But gains in the Nasdaq .IXIC were held back by major technology sto... | Biotechnology firm Regenxbio Inc RGNX.O surged nearly 30% after it entered a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. By Ambar Warrick and Devik Jain Sept 13 (Reuters) - Wall Street indexes on Monday rose from their worst week in sev... | Biotechnology firm Regenxbio Inc RGNX.O surged nearly 30% after it entered a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. But gains in the Nasdaq .IXIC were held back by major technology stocks as investors pivoted to sectors more likely... | Biotechnology firm Regenxbio Inc RGNX.O surged nearly 30% after it entered a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. By Ambar Warrick and Devik Jain Sept 13 (Reuters) - Wall Street indexes on Monday rose from their worst week in sev... | Biotechnology firm Regenxbio Inc RGNX.O surged nearly 30% after it entered a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. But gains in the Nasdaq .IXIC were held back by major technology stocks as investors pivoted to sectors more likely... |
23,920 | 2021-09-13 00:00:00 UTC | Health Care Sector Update for 09/13/2021: MDXG,ITMR,RGNX,ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-09-13-2021%3A-mdxgitmrrgnxabbv-2021-09-13 | null | null | Health care stocks were moderately lower this afternoon, with the NYSE Health Care Index falling 0.4% while the SPDR Health Care Select Sector ETF (XLV) also was down 0.6%.
The Nasdaq Biotechnology index was slipping 0.1%.
In company news, MiMedx (MDXG) tumbled almost 58% after saying its dehydrated human amnion chorio... | Regenxbio (RGNX) jumped out to a nearly 25% advance after announcing a collaboration pact with AbbVie (ABBV) to develop and commercialize its RGX-314 drug candidate as a potential genetic therapy for macular degeneration, diabetic retinopathy, and other chronic retinal diseases. In company news, MiMedx (MDXG) tumbled a... | Regenxbio (RGNX) jumped out to a nearly 25% advance after announcing a collaboration pact with AbbVie (ABBV) to develop and commercialize its RGX-314 drug candidate as a potential genetic therapy for macular degeneration, diabetic retinopathy, and other chronic retinal diseases. Health care stocks were moderately lower... | Regenxbio (RGNX) jumped out to a nearly 25% advance after announcing a collaboration pact with AbbVie (ABBV) to develop and commercialize its RGX-314 drug candidate as a potential genetic therapy for macular degeneration, diabetic retinopathy, and other chronic retinal diseases. Health care stocks were moderately lower... | Regenxbio (RGNX) jumped out to a nearly 25% advance after announcing a collaboration pact with AbbVie (ABBV) to develop and commercialize its RGX-314 drug candidate as a potential genetic therapy for macular degeneration, diabetic retinopathy, and other chronic retinal diseases. Health care stocks were moderately lower... |
23,921 | 2021-09-13 00:00:00 UTC | US STOCKS-Dow, S&P higher on support from energy shares even as tech struggles | ABBV | https://www.nasdaq.com/articles/us-stocks-dow-sp-higher-on-support-from-energy-shares-even-as-tech-struggles-2021-09-13 | null | null | By Ambar Warrick
Sept 13 (Reuters) - Gains in energy stocks pushed the Dow Jones index higher on Monday and kept the S&P 500 in positive territory, with focus shifting to potential changes to corporate taxes and a clutch of data this week.
The Nasdaq .IXIC, however, was pulled lower by a drop in major technology stocks... | Among individual movers, biotechnology firm Regenxbio Inc RGNX.O surged nearly 30% after it entered into a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. By Ambar Warrick Sept 13 (Reuters) - Gains in energy stocks pushed the Dow Jones inde... | Among individual movers, biotechnology firm Regenxbio Inc RGNX.O surged nearly 30% after it entered into a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. By Ambar Warrick Sept 13 (Reuters) - Gains in energy stocks pushed the Dow Jones inde... | Among individual movers, biotechnology firm Regenxbio Inc RGNX.O surged nearly 30% after it entered into a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. By Ambar Warrick Sept 13 (Reuters) - Gains in energy stocks pushed the Dow Jones inde... | Among individual movers, biotechnology firm Regenxbio Inc RGNX.O surged nearly 30% after it entered into a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. Sector-wise, the S&P energy .SPNY was the best performer, gaining 3% as oil prices hi... |
23,922 | 2021-09-13 00:00:00 UTC | XLV, ABBV, BMY, ISRG: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/xlv-abbv-bmy-isrg%3A-large-outflows-detected-at-etf-2021-09-13 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $86.6 million dollar outflow -- that's a 0.3% decrease week over week (from 248,570,000 to 247,92... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.2%, and Intuitive Surgical Inc (Symbol: ISRG) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.2%, and Intuitive Surgical Inc (Symbol: ISRG) is lower by about 0.8%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows t... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.2%, and Intuitive Surgical Inc (Symbol: ISRG) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.2%, and Intuitive Surgical Inc (Symbol: ISRG) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs ... |
23,923 | 2021-09-13 00:00:00 UTC | US STOCKS-Wall Street set to recover from sharp weekly losses | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-street-set-to-recover-from-sharp-weekly-losses-2021-09-13 | null | null | By Ambar Warrick and Devik Jain
Sept 13 (Reuters) - Wall Street indexes were set to rise on Monday after their worst week in several months, with investors keeping a tab on the impact of potential changes to taxation on corporate profits and the effects of inflation on monetary policy.
The indexes lost between 1.6% to ... | Biotechnology firm Regenxbio Inc RGNX.O surged more than 20% after it entered a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. By Ambar Warrick and Devik Jain Sept 13 (Reuters) - Wall Street indexes were set to rise on Monday after their w... | Biotechnology firm Regenxbio Inc RGNX.O surged more than 20% after it entered a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. The August consumer price data, which is due on Tuesday, is also likely to be an important cue for the Fed's dec... | Biotechnology firm Regenxbio Inc RGNX.O surged more than 20% after it entered a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. By Ambar Warrick and Devik Jain Sept 13 (Reuters) - Wall Street indexes were set to rise on Monday after their w... | Biotechnology firm Regenxbio Inc RGNX.O surged more than 20% after it entered a partnership with peer AbbVie ABBV.N to develop and sell a gene therapy candidate for the treatment of chronic retinal diseases. Also on the radar is the Biden government's corporate tax hike plan. Investors will also be watching retail sale... |
23,924 | 2021-09-13 00:00:00 UTC | Why Regenxbio Stock Is Way Up Today | ABBV | https://www.nasdaq.com/articles/why-regenxbio-stock-is-way-up-today-2021-09-13 | null | null | What happened
Regenexbio (NASDAQ: RGNX) stock is shooting higher after the clinical-stage biotech signed a new collaboration deal with AbbVie (NYSE: ABBV), a giant global pharmaceutical company. Investors happy with the generous terms of the deal pushed Regenexbio shares 25.6% higher as of 2:06 p.m. EDT on Monday.
So w... | What happened Regenexbio (NASDAQ: RGNX) stock is shooting higher after the clinical-stage biotech signed a new collaboration deal with AbbVie (NYSE: ABBV), a giant global pharmaceutical company. AbbVie will share costs for upcoming trials that employ subretinal injections in the U.S. and lead global development efforts... | Upfront, AbbVie will pay Regenexbio $370 million for rights to RGX-314, an experimental gene therapy for the treatment of progressive retinal diseases that cause vision loss for millions of older Americans. What happened Regenexbio (NASDAQ: RGNX) stock is shooting higher after the clinical-stage biotech signed a new co... | What happened Regenexbio (NASDAQ: RGNX) stock is shooting higher after the clinical-stage biotech signed a new collaboration deal with AbbVie (NYSE: ABBV), a giant global pharmaceutical company. Today's deal with AbbVie, though, gives the company a lot more cash to work with. Upfront, AbbVie will pay Regenexbio $370 mi... | What happened Regenexbio (NASDAQ: RGNX) stock is shooting higher after the clinical-stage biotech signed a new collaboration deal with AbbVie (NYSE: ABBV), a giant global pharmaceutical company. Today's deal with AbbVie, though, gives the company a lot more cash to work with. Upfront, AbbVie will pay Regenexbio $370 mi... |
23,925 | 2021-09-13 00:00:00 UTC | AbbVie Inks Eye Care Deal With REGENXBIO | ABBV | https://www.nasdaq.com/articles/abbvie-inks-eye-care-deal-with-regenxbio-2021-09-13 | null | null | (RTTNews) - Lake Bluff-based biopharmaceutical company AbbVie (ABBV) has joined hands with Rockville-headquartered REGENXBIO Inc. (RGNX), a clinical-stage biotechnology firm to develop and sell RGX-314, an eye-care therapy, the companies said in a statement on Monday.
RGX-314 is a potential one-time gene therapy for th... | (RTTNews) - Lake Bluff-based biopharmaceutical company AbbVie (ABBV) has joined hands with Rockville-headquartered REGENXBIO Inc. (RGNX), a clinical-stage biotechnology firm to develop and sell RGX-314, an eye-care therapy, the companies said in a statement on Monday. AbbVie will lead the clinical development and comme... | REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead the manufacturing of RGX-314 for commercial supply outside the U.S. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial... | REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development. REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. ... | (RTTNews) - Lake Bluff-based biopharmaceutical company AbbVie (ABBV) has joined hands with Rockville-headquartered REGENXBIO Inc. (RGNX), a clinical-stage biotechnology firm to develop and sell RGX-314, an eye-care therapy, the companies said in a statement on Monday. AbbVie and REGENXBIO will collaborate and share cos... |
23,926 | 2021-09-13 00:00:00 UTC | AbbVie, Regenxbio enter deal to develop retinal disease therapy | ABBV | https://www.nasdaq.com/articles/abbvie-regenxbio-enter-deal-to-develop-retinal-disease-therapy-2021-09-13-0 | null | null | Adds details of deal
Sept 13 (Reuters) - AbbVie ABBV.N and Regenxbio Inc RGNX.O entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, which would give the latter an upfront payment of $370 million.
Regenxbio may potentially receive up to $1.3... | Adds details of deal Sept 13 (Reuters) - AbbVie ABBV.N and Regenxbio Inc RGNX.O entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, which would give the latter an upfront payment of $370 million. AbbVie will lead the clinical development an... | AbbVie will lead the clinical development and commercialization of RGX-314 globally. Adds details of deal Sept 13 (Reuters) - AbbVie ABBV.N and Regenxbio Inc RGNX.O entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, which would give the la... | Adds details of deal Sept 13 (Reuters) - AbbVie ABBV.N and Regenxbio Inc RGNX.O entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, which would give the latter an upfront payment of $370 million. AbbVie will lead the clinical development an... | Adds details of deal Sept 13 (Reuters) - AbbVie ABBV.N and Regenxbio Inc RGNX.O entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, which would give the latter an upfront payment of $370 million. AbbVie will lead the clinical development an... |
23,927 | 2021-09-13 00:00:00 UTC | AbbVie, Regenxbio enter deal to develop retinal disease therapy | ABBV | https://www.nasdaq.com/articles/abbvie-regenxbio-enter-deal-to-develop-retinal-disease-therapy-2021-09-13 | null | null | Sept 13 (Reuters) - AbbVie ABBV.N and Regenxbio Inc RGNX.O have entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, the pharmaceutical companies said on Monday.
AbbVie will give Regenxbio an upfront payment of $370 million, and Regenxbio ma... | Sept 13 (Reuters) - AbbVie ABBV.N and Regenxbio Inc RGNX.O have entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, the pharmaceutical companies said on Monday. AbbVie will give Regenxbio an upfront payment of $370 million, and Regenxbio ma... | Sept 13 (Reuters) - AbbVie ABBV.N and Regenxbio Inc RGNX.O have entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, the pharmaceutical companies said on Monday. AbbVie will give Regenxbio an upfront payment of $370 million, and Regenxbio ma... | Sept 13 (Reuters) - AbbVie ABBV.N and Regenxbio Inc RGNX.O have entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, the pharmaceutical companies said on Monday. AbbVie will give Regenxbio an upfront payment of $370 million, and Regenxbio ma... | Sept 13 (Reuters) - AbbVie ABBV.N and Regenxbio Inc RGNX.O have entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, the pharmaceutical companies said on Monday. AbbVie will give Regenxbio an upfront payment of $370 million, and Regenxbio ma... |
23,928 | 2021-09-11 00:00:00 UTC | These Promising Clinical Results Could Be Huge for Amgen Investors | ABBV | https://www.nasdaq.com/articles/these-promising-clinical-results-could-be-huge-for-amgen-investors-2021-09-11 | null | null | Amgen (NASDAQ: AMGN) recently shared data from its Phase 3 trial of tezepelumab, which it is developing in collaboration with AstraZeneca (NASDAQ: AZN). Tezepelumab was shown to be very effective in reducing "exacerbations and helping lung function and nasal symptoms in patients with severe, uncontrolled asthma and com... | And when AbbVie's (NYSE: ABBV) Humira loses patent protection in the U.S. in 2023, Amgen's Amjevita is set to be the first Humira biosimilar to launch domestically. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Kody Kester owns shares of AbbVie, Amgen, and GlaxoSmithKline. The AAER refers to the average... | And when AbbVie's (NYSE: ABBV) Humira loses patent protection in the U.S. in 2023, Amgen's Amjevita is set to be the first Humira biosimilar to launch domestically. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Kody Kester owns shares of AbbVie, Amgen, and GlaxoSmithKline. This is due to the fact that m... | And when AbbVie's (NYSE: ABBV) Humira loses patent protection in the U.S. in 2023, Amgen's Amjevita is set to be the first Humira biosimilar to launch domestically. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Kody Kester owns shares of AbbVie, Amgen, and GlaxoSmithKline. Tezepelumab was shown to be ve... | And when AbbVie's (NYSE: ABBV) Humira loses patent protection in the U.S. in 2023, Amgen's Amjevita is set to be the first Humira biosimilar to launch domestically. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Kody Kester owns shares of AbbVie, Amgen, and GlaxoSmithKline. This is due to the fact that m... |
23,929 | 2021-09-10 00:00:00 UTC | Daily Dividend Report: BMY,ABBV,CERN,NLY,HPP | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-bmyabbvcernnlyhpp-2021-09-10 | null | null | Bristol Myers Squibb today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents per share on the $.10 par value common stock of the company. The dividend is payable on November 1, 2021 to stockholders of record at the close of business on October 1, 2021.
The board of directors of... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... |
23,930 | 2021-09-10 00:00:00 UTC | Downward Pressures and Flat Earnings Outweigh the AbbVie Inc.'s (NYSE:ABBV) Dividend Yield | ABBV | https://www.nasdaq.com/articles/downward-pressures-and-flat-earnings-outweigh-the-abbvie-inc.s-nyse%3Aabbv-dividend-yield | null | null | By Stjepan Kalinic
This article first appeared on Simply Wall St News .
AbbVie Inc. ( NYSE: ABBV ) recently cratered, as modest yearly gains almost got wiped out in a single session. Meanwhile, downward pressure continues as the price looks to test the support around US$100 for the third time this year.
We will examine... | NYSE: ABBV Recent Price Movement It is no secret that regulators make or break the markets, but few sectors are under their power as much as the Pharmaceuticals. AbbVie Inc. ( NYSE: ABBV ) recently cratered, as modest yearly gains almost got wiped out in a single session. The FDA added new and updated warnings on drugs... | NYSE: ABBV Historic Dividend September 10th, 2021 Payout ratios Dividends are typically paid from company earnings. AbbVie Inc. ( NYSE: ABBV ) recently cratered, as modest yearly gains almost got wiped out in a single session. NYSE: ABBV Recent Price Movement It is no secret that regulators make or break the markets, b... | It's good to see that while profits did not cover AbbVie's dividends, at least they are affordable from a cash perspective.If executives continued paying more in dividends than the company reported in profits, we'd view this as a warning sign.Extraordinarily few companies are capable of persistently paying a dividend t... | NYSE: ABBV Historic Dividend September 10th, 2021 Payout ratios Dividends are typically paid from company earnings. We update our data on AbbVie every 24 hours, so you can always get our latest analysis of its financial health here. Unfortunately, there hasn't been any earnings growth, and the company's dividend histor... |
23,931 | 2021-09-10 00:00:00 UTC | 3 Stocks to Watch in September | ABBV | https://www.nasdaq.com/articles/3-stocks-to-watch-in-september-2021-09-10 | null | null | Betting against a stock market's bullish run is often not a good idea. There's an adage warning investors against shorting stocks because "the market can remain irrational longer than you can remain solvent," but it also makes sense because bull markets typically last longer than market crashes, recessions, or even dep... | AbbVie was particularly hurt by the decision because its arthritis therapy Rinvoq is a JAK-inhibiting prescription drug, and it is supposed to be the pharma's replacement treatment when its mega-selling Humira goes off-patent. The FDA's announcement offset all of the gains AbbVie had made just weeks before after encour... | AbbVie Shares of pharmaceutical giant AbbVie (NYSE: ABBV) just got a major haircut, losing $20 billion in market value after the U.S. Food and Drug Administration said all Janus kinase (JAK) inhibitors for sale in the U.S. must carry a warning label announcing the drugs carry serious side effects, including blood clots... | AbbVie Shares of pharmaceutical giant AbbVie (NYSE: ABBV) just got a major haircut, losing $20 billion in market value after the U.S. Food and Drug Administration said all Janus kinase (JAK) inhibitors for sale in the U.S. must carry a warning label announcing the drugs carry serious side effects, including blood clots... | AbbVie Shares of pharmaceutical giant AbbVie (NYSE: ABBV) just got a major haircut, losing $20 billion in market value after the U.S. Food and Drug Administration said all Janus kinase (JAK) inhibitors for sale in the U.S. must carry a warning label announcing the drugs carry serious side effects, including blood clots... |
23,932 | 2021-09-09 00:00:00 UTC | Drugmaker Endo settles opioid claims by New York, counties for $50 mln | ABBV | https://www.nasdaq.com/articles/drugmaker-endo-settles-opioid-claims-by-new-york-counties-for-%2450-mln-2021-09-10 | null | null | Sept 9 (Reuters) - Drugmaker Endo International Plc ENDP.O on Thursday said it has agreed to pay $50 million to resolve lawsuits by New York state and two of its largest counties related to the sale and marketing of opioids.
Endo said the settlement includes no admission of wrongdoing by Endo or its subsidiaries.
The s... | Claims against AbbVie Inc ABBV.N and Teva Pharmaceutical Industries TEVA.TA remain pending. Sept 9 (Reuters) - Drugmaker Endo International Plc ENDP.O on Thursday said it has agreed to pay $50 million to resolve lawsuits by New York state and two of its largest counties related to the sale and marketing of opioids. The... | Claims against AbbVie Inc ABBV.N and Teva Pharmaceutical Industries TEVA.TA remain pending. Sept 9 (Reuters) - Drugmaker Endo International Plc ENDP.O on Thursday said it has agreed to pay $50 million to resolve lawsuits by New York state and two of its largest counties related to the sale and marketing of opioids. "Wh... | Claims against AbbVie Inc ABBV.N and Teva Pharmaceutical Industries TEVA.TA remain pending. Sept 9 (Reuters) - Drugmaker Endo International Plc ENDP.O on Thursday said it has agreed to pay $50 million to resolve lawsuits by New York state and two of its largest counties related to the sale and marketing of opioids. The... | Claims against AbbVie Inc ABBV.N and Teva Pharmaceutical Industries TEVA.TA remain pending. Sept 9 (Reuters) - Drugmaker Endo International Plc ENDP.O on Thursday said it has agreed to pay $50 million to resolve lawsuits by New York state and two of its largest counties related to the sale and marketing of opioids. The... |
23,933 | 2021-09-09 00:00:00 UTC | Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders? | ABBV | https://www.nasdaq.com/articles/could-this-label-expansion-be-a-blockbuster-for-abbvies-shareholders-2021-09-09 | null | null | AbbVie (NYSE: ABBV) recently announced that its immunology drug Rinvoq had received approval from the European Commission (EC) to treat adolescent and adult patients with moderate-to-severe atopic dermatitis -- commonly known as eczema -- in the European Union (EU).
The decision comes just two months after a recommenda... | AbbVie expects the FDA to decide on Rinvoq's pending psoriatic arthritis and eczema applications in "the next few months following completion of the agency's review of the tofacitinib oral surveillance data," said Vice Chairman Mike Severino in the company's Q2 2021 earnings call. A steady high yielder So even with rec... | A steady high yielder So even with recent news that the FDA will require updated warnings from JAK inhibitors, the EC's approval of Rinvoq for several additional indications this year bodes well for pharma stock AbbVie. AbbVie (NYSE: ABBV) recently announced that its immunology drug Rinvoq had received approval from th... | AbbVie (NYSE: ABBV) recently announced that its immunology drug Rinvoq had received approval from the European Commission (EC) to treat adolescent and adult patients with moderate-to-severe atopic dermatitis -- commonly known as eczema -- in the European Union (EU). A steady high yielder So even with recent news that t... | AbbVie (NYSE: ABBV) recently announced that its immunology drug Rinvoq had received approval from the European Commission (EC) to treat adolescent and adult patients with moderate-to-severe atopic dermatitis -- commonly known as eczema -- in the European Union (EU). This could be positive news on multiple fronts for bo... |
23,934 | 2021-09-08 00:00:00 UTC | Implied RWL Analyst Target Price: $83 | ABBV | https://www.nasdaq.com/articles/implied-rwl-analyst-target-price%3A-%2483-2021-09-08 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P 500 Revenue ETF (Sy... | Although ABBV has traded at a recent price of $109.03/share, the average analyst target is 14.80% higher at $125.17/share. Invesco S&P 500 Revenue ETF RWL $75.48 $82.97 9.92% AbbVie Inc ABBV $109.03 $125.17 14.80% Vornado Realty Trust VNO $42.02 $47.62 13.34% NiSource Inc. NI $24.72 $28.00 13.27% Are analysts justified... | Three of RWL's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Vornado Realty Trust (Symbol: VNO), and NiSource Inc. (Symbol: NI). Invesco S&P 500 Revenue ETF RWL $75.48 $82.97 9.92% AbbVie Inc ABBV $109.03 $125.17 14.80% Vornado Realty Trust VNO $42.02 $47.62 13.34... | Three of RWL's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Vornado Realty Trust (Symbol: VNO), and NiSource Inc. (Symbol: NI). Although ABBV has traded at a recent price of $109.03/share, the average analyst target is 14.80% higher at $125.17/share. Below is a t... | Invesco S&P 500 Revenue ETF RWL $75.48 $82.97 9.92% AbbVie Inc ABBV $109.03 $125.17 14.80% Vornado Realty Trust VNO $42.02 $47.62 13.34% NiSource Inc. NI $24.72 $28.00 13.27% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RWL's underly... |
23,935 | 2021-09-08 00:00:00 UTC | Should You Buy AbbVie Stock After The Recent 7% Fall? | ABBV | https://www.nasdaq.com/articles/should-you-buy-abbvie-stock-after-the-recent-7-fall-2021-09-08 | null | null | [Updated: Sep 3, 2021] ABBV Stock Decline
The stock price of AbbVie (NYSE: ABBV) reached its 52-week high of around $121 just last week before a recent sell-off in ABBV stock, especially after the U.S. FDA stated that all janus kinase inhibitors approved for arthritis treatment should carry a heart-risk warning on the ... | Rinvoq has great future prospects, given that Abbvie’s top-selling drug – Humira – which is also used for arthritis, among other indications it is approved for, will lose its market exclusivity in 2023. According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years... | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for ABBV stock average 5% in the next one-month (twenty-one trading days) period after experiencing a 7% drop over the previous week (five trading days). You can test the ans... | [Updated: Sep 3, 2021] ABBV Stock Decline The stock price of AbbVie (NYSE: ABBV) reached its 52-week high of around $121 just last week before a recent sell-off in ABBV stock, especially after the U.S. FDA stated that all janus kinase inhibitors approved for arthritis treatment should carry a heart-risk warning on the ... | Since investors were looking upon Rinvoq to compensate for the decline in Humira’s sales after its patent expiration, ABBV stock was hit harder compared to other stocks that sell janus kinase inhibitors treatment for arthritis, including Pfizer and Eli Lilly, both of which saw only a 1% decline over the last five tradi... |
23,936 | 2021-09-07 00:00:00 UTC | AbbVie is Oversold | ABBV | https://www.nasdaq.com/articles/abbvie-is-oversold-2021-09-07 | null | null | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie Inc (Symbol: ABBV) presently has an... | A bullish investor could look at ABBV's 27.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. AbbVie Inc (Symbol: ABBV) presently has an excellent rank, in the top 25% of the coverage universe, which sugges... | In the case of AbbVie Inc, the RSI reading has hit 27.2 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 53.8. Indeed, ABBV's recent annualized dividend of 5.2/share (currently paid in quarterly installments) works out to an annual yield of 4.66% based upon th... | In the case of AbbVie Inc, the RSI reading has hit 27.2 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 53.8. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABBV is its dividend history. AbbVie Inc (Sym... | Indeed, ABBV's recent annualized dividend of 5.2/share (currently paid in quarterly installments) works out to an annual yield of 4.66% based upon the recent $111.62 share price. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABBV is its dividend history. AbbVie ... |
23,937 | 2021-09-07 00:00:00 UTC | Top Health Care Stocks To Buy In September 2021? 4 To Watch | ABBV | https://www.nasdaq.com/articles/top-health-care-stocks-to-buy-in-september-2021-4-to-watch-2021-09-07 | null | null | 4 Trending Health Care Stocks To Consider Adding To Your Watchlist This Week
Booster shots appear to be the magic phrase in the current fight against the coronavirus pandemic. As such, we could see health care stocks coming back into play in the stock market now. For the most part, the matter of booster shots has been ... | Best Health Care Stocks To Watch Right Now RenovoRx Inc. (NASDAQ: RNXT) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Adagio Therapeutics Inc. (NASDAQ: ADGI) RenovoRx Inc. RenovoRx is a biopharmaceutical company with headquarters in Silicon Valley, California. 3 Retail Stocks To Know AbbVie Inc. AbbVie is a biop... | Best Health Care Stocks To Watch Right Now RenovoRx Inc. (NASDAQ: RNXT) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Adagio Therapeutics Inc. (NASDAQ: ADGI) RenovoRx Inc. RenovoRx is a biopharmaceutical company with headquarters in Silicon Valley, California. 3 Retail Stocks To Know AbbVie Inc. AbbVie is a biop... | Best Health Care Stocks To Watch Right Now RenovoRx Inc. (NASDAQ: RNXT) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Adagio Therapeutics Inc. (NASDAQ: ADGI) RenovoRx Inc. RenovoRx is a biopharmaceutical company with headquarters in Silicon Valley, California. 3 Retail Stocks To Know AbbVie Inc. AbbVie is a biop... | Best Health Care Stocks To Watch Right Now RenovoRx Inc. (NASDAQ: RNXT) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Adagio Therapeutics Inc. (NASDAQ: ADGI) RenovoRx Inc. RenovoRx is a biopharmaceutical company with headquarters in Silicon Valley, California. 3 Retail Stocks To Know AbbVie Inc. AbbVie is a biop... |
23,938 | 2021-09-02 00:00:00 UTC | 7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In | ABBV | https://www.nasdaq.com/articles/7-healthcare-stocks-to-buy-before-%243.5-trillion-floods-in-2021-09-02 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Healthcare stocks are once again in the spotlight as the delta variant rides a new wave of coronavirus infections across the globe. As countries batten down the hatches again, it’s not surprising to see investors once again turn their attention towards the ... | AbbVie (NYSE:ABBV) Baxter International (NYSE:BAX) Health Care Select Sector SPDR Fund (NYSEARCA:XLV) Johnson & Johnson (NYSE:JNJ) Medtronic (NYSE:MDT) UnitedHealth Group (NYSE:UNH) Vertex (NASDAQ:VRTX) Healthcare Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Pio... | AbbVie (NYSE:ABBV) Baxter International (NYSE:BAX) Health Care Select Sector SPDR Fund (NYSEARCA:XLV) Johnson & Johnson (NYSE:JNJ) Medtronic (NYSE:MDT) UnitedHealth Group (NYSE:UNH) Vertex (NASDAQ:VRTX) Healthcare Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Pio... | AbbVie (NYSE:ABBV) Baxter International (NYSE:BAX) Health Care Select Sector SPDR Fund (NYSEARCA:XLV) Johnson & Johnson (NYSE:JNJ) Medtronic (NYSE:MDT) UnitedHealth Group (NYSE:UNH) Vertex (NASDAQ:VRTX) Healthcare Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Pio... | AbbVie (NYSE:ABBV) Baxter International (NYSE:BAX) Health Care Select Sector SPDR Fund (NYSEARCA:XLV) Johnson & Johnson (NYSE:JNJ) Medtronic (NYSE:MDT) UnitedHealth Group (NYSE:UNH) Vertex (NASDAQ:VRTX) Healthcare Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Pio... |
23,939 | 2021-09-02 00:00:00 UTC | First Week of February 2022 Options Trading For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/first-week-of-february-2022-options-trading-for-abbvie-abbv-2021-09-02 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading this week, for the February 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 169 days until expiration the newly trading contracts represent a potential opportunity for selle... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $110.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $115.00 strike price has a current bid of $5.70. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new February 2022 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $115.00 strike highlighted in red: Consi... |
23,940 | 2021-09-01 00:00:00 UTC | Notable Wednesday Option Activity: GOOGL, ABBV, CBRE | ABBV | https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-googl-abbv-cbre-2021-09-01 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Alphabet Inc (Symbol: GOOGL), where a total of 42,703 contracts have traded so far, representing approximately 4.3 million underlying shares. That amounts to about 407.5% of GOOGL's average daily trading volume over ... | Particularly high volume was seen for the $123 strike call option expiring September 03, 2021, with 12,386 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing GOOGL's trailing twelve month trading history, with the $2950 strike highlighted in orange... | Below is a chart showing GOOGL's trailing twelve month trading history, with the $2950 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 193,589 contracts thus far today. Particularly high volume was seen for the $123 strike call option expiring September 03, 2021, with 12,386 cont... | Below is a chart showing ABBV's trailing twelve month trading history, with the $123 strike highlighted in orange: And CBRE Group Inc (Symbol: CBRE) saw options trading volume of 40,879 contracts, representing approximately 4.1 million underlying shares or approximately 338% of CBRE's average daily trading volume over ... | Particularly high volume was seen for the $123 strike call option expiring September 03, 2021, with 12,386 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $123 strike highlighted in orange: ... |
23,941 | 2021-09-01 00:00:00 UTC | U.S. FDA seeks new warnings on drugs from Pfizer, Lilly and AbbVie | ABBV | https://www.nasdaq.com/articles/u.s.-fda-seeks-new-warnings-on-drugs-from-pfizer-lilly-and-abbvie-2021-09-01-0 | null | null | Adds Pfizer, Lilly and analyst comments
Sept 1 (Reuters) - The U.S. drug regulator has asked Pfizer PFE.N, Eli Lilly & Co LLY.N and AbbVie ABBV.N to include information about risks of serious conditions and death from the use of their drugs that belong to a class of treatments known as JAK inhibitors.
The warnings on W... | The FDA said Lilly's drug Olumiant and AbbVie's Rinvoq have similar operating mechanisms, leading to the possibility of risks seen in the Xeljanz safety trial. Adds Pfizer, Lilly and analyst comments Sept 1 (Reuters) - The U.S. drug regulator has asked Pfizer PFE.N, Eli Lilly & Co LLY.N and AbbVie ABBV.N to include inf... | Adds Pfizer, Lilly and analyst comments Sept 1 (Reuters) - The U.S. drug regulator has asked Pfizer PFE.N, Eli Lilly & Co LLY.N and AbbVie ABBV.N to include information about risks of serious conditions and death from the use of their drugs that belong to a class of treatments known as JAK inhibitors. The FDA said Lill... | Adds Pfizer, Lilly and analyst comments Sept 1 (Reuters) - The U.S. drug regulator has asked Pfizer PFE.N, Eli Lilly & Co LLY.N and AbbVie ABBV.N to include information about risks of serious conditions and death from the use of their drugs that belong to a class of treatments known as JAK inhibitors. The FDA said Lill... | Adds Pfizer, Lilly and analyst comments Sept 1 (Reuters) - The U.S. drug regulator has asked Pfizer PFE.N, Eli Lilly & Co LLY.N and AbbVie ABBV.N to include information about risks of serious conditions and death from the use of their drugs that belong to a class of treatments known as JAK inhibitors. The FDA is curren... |
23,942 | 2021-09-01 00:00:00 UTC | Why AbbVie Is Down More Than 7% Today | ABBV | https://www.nasdaq.com/articles/why-abbvie-is-down-more-than-7-today-2021-09-01 | null | null | What happened
Shares of drugmaker AbbVie (NYSE: ABBV) are off by 7.8% in Wednesday afternoon's trading session following a decision from the Food and Drug Administration to require a heart-risk warning on the label of its arthritis treatment Rinvoq.
So what
As part of its routine reviews of clinical trial data, the FDA... | What happened Shares of drugmaker AbbVie (NYSE: ABBV) are off by 7.8% in Wednesday afternoon's trading session following a decision from the Food and Drug Administration to require a heart-risk warning on the label of its arthritis treatment Rinvoq. AbbVie's Rinvoq is one of these JAK-inhibiting prescription drugs. Whi... | While AbbVie is best known for its arthritis, plaque psoriasis, and Crohn's disease treatment Humira, Rinvoq was one of the pharmaceutical franchises hoped to help replace the loss of sales linked to the expiration of Humira's patents. What happened Shares of drugmaker AbbVie (NYSE: ABBV) are off by 7.8% in Wednesday a... | What happened Shares of drugmaker AbbVie (NYSE: ABBV) are off by 7.8% in Wednesday afternoon's trading session following a decision from the Food and Drug Administration to require a heart-risk warning on the label of its arthritis treatment Rinvoq. AbbVie's Rinvoq is one of these JAK-inhibiting prescription drugs. Whi... | AbbVie's Rinvoq is one of these JAK-inhibiting prescription drugs. What happened Shares of drugmaker AbbVie (NYSE: ABBV) are off by 7.8% in Wednesday afternoon's trading session following a decision from the Food and Drug Administration to require a heart-risk warning on the label of its arthritis treatment Rinvoq. Whi... |
23,943 | 2021-09-01 00:00:00 UTC | 3 Top Warren Buffett Stocks to Buy in September | ABBV | https://www.nasdaq.com/articles/3-top-warren-buffett-stocks-to-buy-in-september-2021-09-01 | null | null | Warren Buffett has plenty to smile about these days. Shares of his beloved Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) have soared more than 20% so far in 2021. Unlike last year, Berkshire stock is outperforming the S&P 500.
Quite a few of Berkshire's equity holdings have generated tremendous year-to-date gains. How... | AbbVie has a short-term growth problem, with its blockbuster autoimmune-disease drug Humira facing biosimilar rivals in the U.S. beginning in 2023. AbbVie: Checking off all the boxes Some stocks offer great dividends. Few stocks check off all of these boxes, but AbbVie (NYSE: ABBV) does. | Keith Speights owns shares of AbbVie, Amazon, Apple, and Berkshire Hathaway (B shares). AbbVie: Checking off all the boxes Some stocks offer great dividends. Few stocks check off all of these boxes, but AbbVie (NYSE: ABBV) does. | AbbVie: Checking off all the boxes Some stocks offer great dividends. Few stocks check off all of these boxes, but AbbVie (NYSE: ABBV) does. Nearly any income-seeking investor will find AbbVie's dividend yield of 4.4% quite appealing. | AbbVie: Checking off all the boxes Some stocks offer great dividends. Few stocks check off all of these boxes, but AbbVie (NYSE: ABBV) does. Nearly any income-seeking investor will find AbbVie's dividend yield of 4.4% quite appealing. |
23,944 | 2021-09-01 00:00:00 UTC | 4 Top Stock Trades for Thursday: Ethereum, ABBV, CHWY, LCID | ABBV | https://www.nasdaq.com/articles/4-top-stock-trades-for-thursday%3A-ethereum-abbv-chwy-lcid-2021-09-01 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
On the first day of trading for September, the Nasdaq Composite ripped to new all-time highs, although the stock market stumbled late in the session. That said, let’s look at a few top stock trades as we approach the long holiday weekend.
Top Stock Trades f... | Click to Enlarge Source: Chart courtesy of TrendSpider What in the world happened to AbbVie (NYSE:ABBV), a name that had been a very consistent performer over the past year? 2: AbbVie (ABBV) AbbVie found support from a number of measures, including the 50-week moving average, the weekly VWAP and the $109 level (which w... | 2: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider What in the world happened to AbbVie (NYSE:ABBV), a name that had been a very consistent performer over the past year? AbbVie found support from a number of measures, including the 50-week moving average, the weekly VWAP and the $109 level (which w... | The post 4 Top Stock Trades for Thursday: Ethereum, ABBV, CHWY, LCID appeared first on InvestorPlace. 2: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider What in the world happened to AbbVie (NYSE:ABBV), a name that had been a very consistent performer over the past year? | The post 4 Top Stock Trades for Thursday: Ethereum, ABBV, CHWY, LCID appeared first on InvestorPlace. 2: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider What in the world happened to AbbVie (NYSE:ABBV), a name that had been a very consistent performer over the past year? |
23,945 | 2021-09-01 00:00:00 UTC | 3 Investing Strategies to Grow Your Money Like Magic | ABBV | https://www.nasdaq.com/articles/3-investing-strategies-to-grow-your-money-like-magic-2021-09-01 | null | null | I used to just save my money, until I realized I could grow it -- and grow it powerfully, thanks to the magic of compounding. When your money is compounding in the stock market, it grows by increasing amounts over time, over the long run. So your $10,000 investment might grow by, say, $1,000 in your first year, but yea... | Selena Maranjian owns shares of AbbVie, Amazon, Apple, Costco Wholesale, Facebook, Intuitive Surgical, Netflix, PayPal Holdings, and Starbucks. AbbVie 4.35% 17.9% Automatic Data Processing 1.78% 11.9% Cisco Systems 2.5% 7.3% Clorox 2.81% 7.7% Coca-Cola 3.02% 3.7% Corning 2.36% 12.2% Lowe's 1.55% 18% Nike 0.66% 11.4% St... | Selena Maranjian owns shares of AbbVie, Amazon, Apple, Costco Wholesale, Facebook, Intuitive Surgical, Netflix, PayPal Holdings, and Starbucks. AbbVie 4.35% 17.9% Automatic Data Processing 1.78% 11.9% Cisco Systems 2.5% 7.3% Clorox 2.81% 7.7% Coca-Cola 3.02% 3.7% Corning 2.36% 12.2% Lowe's 1.55% 18% Nike 0.66% 11.4% St... | AbbVie 4.35% 17.9% Automatic Data Processing 1.78% 11.9% Cisco Systems 2.5% 7.3% Clorox 2.81% 7.7% Coca-Cola 3.02% 3.7% Corning 2.36% 12.2% Lowe's 1.55% 18% Nike 0.66% 11.4% Starbucks 1.56% 17.6% Visa 0.55% 18% Walgreens Boots Alliance 3.94% 5% Waste Management 1.49% 7% Data source: Yahoo! Selena Maranjian owns shares ... | AbbVie 4.35% 17.9% Automatic Data Processing 1.78% 11.9% Cisco Systems 2.5% 7.3% Clorox 2.81% 7.7% Coca-Cola 3.02% 3.7% Corning 2.36% 12.2% Lowe's 1.55% 18% Nike 0.66% 11.4% Starbucks 1.56% 17.6% Visa 0.55% 18% Walgreens Boots Alliance 3.94% 5% Waste Management 1.49% 7% Data source: Yahoo! Selena Maranjian owns shares ... |
23,946 | 2021-09-01 00:00:00 UTC | U.S. FDA seeks new warnings on drugs from Pfizer, Lilly and AbbVie | ABBV | https://www.nasdaq.com/articles/u.s.-fda-seeks-new-warnings-on-drugs-from-pfizer-lilly-and-abbvie-2021-09-01 | null | null | Sept 1 (Reuters) - The U.S. drugs regulator on Wednesday asked Pfizer Inc PFE.N, Eli Lilly & Co LLY.N and AbbVie Inc ABBV.N to include information about risks of serious conditions and death from the use of a class of treatments known as JAK inhibitors.
The warnings stem from the U.S. Food and Drug Administration's rev... | Sept 1 (Reuters) - The U.S. drugs regulator on Wednesday asked Pfizer Inc PFE.N, Eli Lilly & Co LLY.N and AbbVie Inc ABBV.N to include information about risks of serious conditions and death from the use of a class of treatments known as JAK inhibitors. The FDA said the Lilly drug Olumiant and AbbVie's Rinvoq have simi... | Sept 1 (Reuters) - The U.S. drugs regulator on Wednesday asked Pfizer Inc PFE.N, Eli Lilly & Co LLY.N and AbbVie Inc ABBV.N to include information about risks of serious conditions and death from the use of a class of treatments known as JAK inhibitors. AbbVie shares fell 7%, while Pfizer and Eli Lilly were slightly lo... | Sept 1 (Reuters) - The U.S. drugs regulator on Wednesday asked Pfizer Inc PFE.N, Eli Lilly & Co LLY.N and AbbVie Inc ABBV.N to include information about risks of serious conditions and death from the use of a class of treatments known as JAK inhibitors. AbbVie shares fell 7%, while Pfizer and Eli Lilly were slightly lo... | Sept 1 (Reuters) - The U.S. drugs regulator on Wednesday asked Pfizer Inc PFE.N, Eli Lilly & Co LLY.N and AbbVie Inc ABBV.N to include information about risks of serious conditions and death from the use of a class of treatments known as JAK inhibitors. AbbVie shares fell 7%, while Pfizer and Eli Lilly were slightly lo... |
23,947 | 2021-08-31 00:00:00 UTC | What's Happening With Merck Stock? | ABBV | https://www.nasdaq.com/articles/whats-happening-with-merck-stock-2021-08-31 | null | null | The stock price of Merck (NYSE: MRK) has seen a 2.4% drop over the last five trading sessions led by a recent sell-off in large-cap pharmaceuticals stocks over the past week or so, with Johnson & Johnson, Pfizer, and Bristol Myers Squibb also falling around 3% each. These stocks have seen double-digit gains so far this... | This can be attributed to rising concerns of slowing sales for some of its drugs, such as, Januvia and Janumet, along with the impact of the Covid-19 pandemic on its vaccines, including Gardasil. Try the Trefis machine learning engine above to see for yourself how Merck stock is likely to behave after any specific gain... | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for MRK stock average around 2.1% in the next one-month (twenty-one trading days) period after experiencing a 2.4% drop over the previous week (five trading days), implying t... | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for MRK stock average around 2.1% in the next one-month (twenty-one trading days) period after experiencing a 2.4% drop over the previous week (five trading days), implying t... | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for MRK stock average around 2.1% in the next one-month (twenty-one trading days) period after experiencing a 2.4% drop over the previous week (five trading days), implying t... |
23,948 | 2021-08-30 00:00:00 UTC | Does the Pullback in This Pharma Stock Create a Buying Opportunity? | ABBV | https://www.nasdaq.com/articles/does-the-pullback-in-this-pharma-stock-create-a-buying-opportunity-2021-08-30 | null | null | Since biotech company Amgen (NASDAQ: AMGN) reported its second-quarter earnings earlier this month, its shares have fallen 9%. The market's reaction occurred despite Amgen's performance; even against the COVID-19 headwinds the company has faced this year, it was able to exceed analysts' revenue and earnings-per-share e... | For more context, Amgen's net debt-to-EBITDA ratio is lower or more conservative than AbbVie's 3.4 ratio ($73.6 billion in net debt/$21.3 billion in annualized EBITDA through the first half of this year), but riskier than Johnson & Johnson's impressive 0.6 ratio ($16 billion/$28.2 billion). See the 10 stocks *Stock Adv... | For more context, Amgen's net debt-to-EBITDA ratio is lower or more conservative than AbbVie's 3.4 ratio ($73.6 billion in net debt/$21.3 billion in annualized EBITDA through the first half of this year), but riskier than Johnson & Johnson's impressive 0.6 ratio ($16 billion/$28.2 billion). See the 10 stocks *Stock Adv... | For more context, Amgen's net debt-to-EBITDA ratio is lower or more conservative than AbbVie's 3.4 ratio ($73.6 billion in net debt/$21.3 billion in annualized EBITDA through the first half of this year), but riskier than Johnson & Johnson's impressive 0.6 ratio ($16 billion/$28.2 billion). See the 10 stocks *Stock Adv... | For more context, Amgen's net debt-to-EBITDA ratio is lower or more conservative than AbbVie's 3.4 ratio ($73.6 billion in net debt/$21.3 billion in annualized EBITDA through the first half of this year), but riskier than Johnson & Johnson's impressive 0.6 ratio ($16 billion/$28.2 billion). See the 10 stocks *Stock Adv... |
23,949 | 2021-08-30 00:00:00 UTC | Biotech Stocks Facing FDA Decision In September 2021 | ABBV | https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-september-2021-2021-08-30 | null | null | (RTTNews) - As August draws to a close, let us take a look back at some of the regulatory headlines from that eventful month and look forward to what September has in store.
A new treatment for Pompe disease, Sanofi's Nexviazyme, was approved by the FDA on Aug.6. The company already has one approved Pompe disease drug,... | (RTTNews) - As August draws to a close, let us take a look back at some of the regulatory headlines from that eventful month and look forward to what September has in store. This drug is already approved for the treatment of cataplexy or excessive daytime sleepiness in patients seven years or older with narcolepsy. On ... | A new treatment for Pompe disease, Sanofi's Nexviazyme, was approved by the FDA on Aug.6. The company already has one approved Pompe disease drug, which is sold as Myozyme in Europe and Lumizyme in the U.S. On Aug.23, Pfizer-BioNTech COVID-19 Vaccine became the first to receive full FDA approval for the prevention of C... | A new treatment for Pompe disease, Sanofi's Nexviazyme, was approved by the FDA on Aug.6. On Aug.23, Pfizer-BioNTech COVID-19 Vaccine became the first to receive full FDA approval for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine will now be marketed as Comirnaty and will also... | (RTTNews) - As August draws to a close, let us take a look back at some of the regulatory headlines from that eventful month and look forward to what September has in store. A new treatment for Pompe disease, Sanofi's Nexviazyme, was approved by the FDA on Aug.6. On Aug.23, Pfizer-BioNTech COVID-19 Vaccine became the f... |
23,950 | 2021-08-29 00:00:00 UTC | Best Stocks To Invest In 2021? 5 Health Care Stocks to Watch Now | ABBV | https://www.nasdaq.com/articles/best-stocks-to-invest-in-2021-5-health-care-stocks-to-watch-now-2021-08-29 | null | null | 5 Top Health Care Stocks For Your September 2021 Watchlist
With the global rebound in coronavirus cases courtesy of the highly infectious Delta variant, health care stocks appear to be back in play. If anything, focus on this sector of the stock market would be higher than ever. When you consider the recent alarming up... | Top Health Care Stocks To Watch Today Neurometrix Inc. (NASDAQ: NURO) AbbVie Inc. (NYSE: ABBV) Novavax Inc. (NASDAQ: NVAX) Johnson & Johnson (NYSE: JNJ) RenovoRx Inc. (NASDAQ: RNXT) Neurometrix Inc. Neurometrix is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation-based medical devices.... | Top Health Care Stocks To Watch Today Neurometrix Inc. (NASDAQ: NURO) AbbVie Inc. (NYSE: ABBV) Novavax Inc. (NASDAQ: NVAX) Johnson & Johnson (NYSE: JNJ) RenovoRx Inc. (NASDAQ: RNXT) Neurometrix Inc. Neurometrix is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation-based medical devices.... | Top Health Care Stocks To Watch Today Neurometrix Inc. (NASDAQ: NURO) AbbVie Inc. (NYSE: ABBV) Novavax Inc. (NASDAQ: NVAX) Johnson & Johnson (NYSE: JNJ) RenovoRx Inc. (NASDAQ: RNXT) Neurometrix Inc. Neurometrix is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation-based medical devices.... | Top Health Care Stocks To Watch Today Neurometrix Inc. (NASDAQ: NURO) AbbVie Inc. (NYSE: ABBV) Novavax Inc. (NASDAQ: NVAX) Johnson & Johnson (NYSE: JNJ) RenovoRx Inc. (NASDAQ: RNXT) Neurometrix Inc. Neurometrix is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation-based medical devices.... |
23,951 | 2021-08-29 00:00:00 UTC | Could These Clinical Results Mean Profit for AbbVie Shareholders? | ABBV | https://www.nasdaq.com/articles/could-these-clinical-results-mean-profit-for-abbvie-shareholders-2021-08-29 | null | null | Earlier this month, pharma giant AbbVie (NYSE: ABBV) reported the results from its phase 3 clinical trial testing of atogepant for the preventive treatment of migraine in adults who met the criteria for episodic migraine.
Let's take a look at why the results of the study could soon lead to an approval from the U.S. Foo... | AbbVie is expecting that its Imbruvica and Venclexta combo will be approved next year to treat both stage 1 chronic lymphocytic leukemia and relapsed or refractory mantle cell lymphoma, which should also lead to future growth for the two oncology drugs. Earlier this month, pharma giant AbbVie (NYSE: ABBV) reported the ... | Earlier this month, pharma giant AbbVie (NYSE: ABBV) reported the results from its phase 3 clinical trial testing of atogepant for the preventive treatment of migraine in adults who met the criteria for episodic migraine. Let's take a look at why the results of the study could soon lead to an approval from the U.S. Foo... | Earlier this month, pharma giant AbbVie (NYSE: ABBV) reported the results from its phase 3 clinical trial testing of atogepant for the preventive treatment of migraine in adults who met the criteria for episodic migraine. This would greatly complement AbbVie's existing migraine drug portfolio, which consists of Botox (... | Earlier this month, pharma giant AbbVie (NYSE: ABBV) reported the results from its phase 3 clinical trial testing of atogepant for the preventive treatment of migraine in adults who met the criteria for episodic migraine. Let's take a look at why the results of the study could soon lead to an approval from the U.S. Foo... |
23,952 | 2021-08-28 00:00:00 UTC | AbbVie's (NYSE:ABBV) investors will be pleased with their stellar 134% return over the last five years | ABBV | https://www.nasdaq.com/articles/abbvies-nyse%3Aabbv-investors-will-be-pleased-with-their-stellar-134-return-over-the-last | null | null | The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up more than the market average. Unfortunately for shareholders, while the AbbVie Inc. (NYSE:ABBV) share price is up 86% in the last five years, that's less than the market return. However, if you include ... | Unfortunately for shareholders, while the AbbVie Inc. (NYSE:ABBV) share price is up 86% in the last five years, that's less than the market return. Over half a decade, AbbVie managed to grow its earnings per share at 1.3% a year. NYSE:ABBV Earnings Per Share Growth August 28th 2021 Dive deeper into AbbVie's key metrics... | Unfortunately for shareholders, while the AbbVie Inc. (NYSE:ABBV) share price is up 86% in the last five years, that's less than the market return. NYSE:ABBV Earnings Per Share Growth August 28th 2021 Dive deeper into AbbVie's key metrics by checking this interactive graph of AbbVie's earnings, revenue and cash flow. O... | Unfortunately for shareholders, while the AbbVie Inc. (NYSE:ABBV) share price is up 86% in the last five years, that's less than the market return. We note that for AbbVie the TSR over the last 5 years was 134%, which is better than the share price return mentioned above. Over half a decade, AbbVie managed to grow its ... | Unfortunately for shareholders, while the AbbVie Inc. (NYSE:ABBV) share price is up 86% in the last five years, that's less than the market return. We note that for AbbVie the TSR over the last 5 years was 134%, which is better than the share price return mentioned above. Over half a decade, AbbVie managed to grow its ... |
23,953 | 2021-08-28 00:00:00 UTC | 5 High-Yield Dividend Stocks That Can Double Your Money by 2029 | ABBV | https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-that-can-double-your-money-by-2029-2021-08-28 | null | null | There are a lot of ways to make money on Wall Street. But if there's one common theme among the best-performing portfolios, it's that they're often reliant on dividend stocks.
In 2013, J.P. Morgan Asset Management released a report that demonstrated just how dominant dividend stocks are, relative to public companies th... | Even with the potential for biosimilar competition in the U.S. in the coming years, Humira's multiple approved indications and generally strong pricing power provide a runway for AbbVie to generate significant cash flow from its top drug. AbbVie: 4.4% yield On the other end of the high-yield dividend spectrum, at least... | AbbVie: 4.4% yield On the other end of the high-yield dividend spectrum, at least on this list, is pharmaceutical stock AbbVie (NYSE: ABBV). Considering its 4.4% yield, its modest growth potential, and its insane value proposition, AbbVie has all the tools needed to double investors' money by 2029, if not sooner. There... | AbbVie: 4.4% yield On the other end of the high-yield dividend spectrum, at least on this list, is pharmaceutical stock AbbVie (NYSE: ABBV). Considering its 4.4% yield, its modest growth potential, and its insane value proposition, AbbVie has all the tools needed to double investors' money by 2029, if not sooner. There... | AbbVie: 4.4% yield On the other end of the high-yield dividend spectrum, at least on this list, is pharmaceutical stock AbbVie (NYSE: ABBV). Considering its 4.4% yield, its modest growth potential, and its insane value proposition, AbbVie has all the tools needed to double investors' money by 2029, if not sooner. There... |
23,954 | 2021-08-27 00:00:00 UTC | The 3 Best Biotech Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/the-3-best-biotech-stocks-to-buy-right-now-2021-08-27 | null | null | Investing in biotech companies is hard. Shareholders are often subject to wild price swings based on results that may not translate to future studies. But when a drug succeeds, the gains can be extraordinary. That's why it pays to be diversified and make sure you are comfortable with the level of risk in any stock you ... | Next, AbbVie licensed CD47 assets from Chinese biotech I-MAB last September. The company specializes in treating cystic fibrosis (CF) -- a disease where mucus builds up in organs, most dangerously in the lungs. That's especially true after it stopped its trial to treat a rare genetic disorder affecting the liver and lu... | Next, AbbVie licensed CD47 assets from Chinese biotech I-MAB last September. ALX Oncology (NASDAQ: ALXO), Vertex Pharmaceuticals (NASDAQ: VRTX), and Beam Therapeutics (NASDAQ: BEAM) are at different stages of the company lifecycle. The Motley Fool owns shares of and recommends CRISPR Therapeutics, Editas Medicine, and ... | Next, AbbVie licensed CD47 assets from Chinese biotech I-MAB last September. ALX Oncology (NASDAQ: ALXO), Vertex Pharmaceuticals (NASDAQ: VRTX), and Beam Therapeutics (NASDAQ: BEAM) are at different stages of the company lifecycle. Vertex Pharmaceuticals If you are searching for a more established company in the biotec... | Next, AbbVie licensed CD47 assets from Chinese biotech I-MAB last September. ALX Oncology (NASDAQ: ALXO), Vertex Pharmaceuticals (NASDAQ: VRTX), and Beam Therapeutics (NASDAQ: BEAM) are at different stages of the company lifecycle. Vertex's first CF drug was approved in 2012. |
23,955 | 2021-08-27 00:00:00 UTC | 2 Healthcare Stocks That Could Make You Richer | ABBV | https://www.nasdaq.com/articles/2-healthcare-stocks-that-could-make-you-richer-2021-08-27 | null | null | Finding stocks that have true staying power for your portfolio isn't always easy. In today's historically overpriced market that could potentially be on the verge of another correction, it's more important than ever to focus on high-quality companies that can lend sustained growth to your holdings. Companies operating ... | AbbVie also has plenty of other golden eggs in its basket, such as Skyrizi (for moderate to severe plaque psoriasis), Rinvoq (for rheumatoid arthritis), and Imbruvica (for multiple types of blood cancer). AbbVie is a rock-solid pick for buy-and-hold investors seeking to add a dose of stability, consistent growth, and a... | AbbVie Pharmaceutical stock AbbVie (NYSE: ABBV) is another premium buy in the healthcare industry that can help investors snag consistent portfolio returns in the form of both share-price increases and quarterly dividends. However, it's AbbVie's dividend that really takes the cake. AbbVie is one of a very short list of... | AbbVie Pharmaceutical stock AbbVie (NYSE: ABBV) is another premium buy in the healthcare industry that can help investors snag consistent portfolio returns in the form of both share-price increases and quarterly dividends. However, it's AbbVie's dividend that really takes the cake. AbbVie is one of a very short list of... | AbbVie Pharmaceutical stock AbbVie (NYSE: ABBV) is another premium buy in the healthcare industry that can help investors snag consistent portfolio returns in the form of both share-price increases and quarterly dividends. However, it's AbbVie's dividend that really takes the cake. AbbVie is one of a very short list of... |
23,956 | 2021-08-27 00:00:00 UTC | This Warren Buffett Dividend Stock Is Still Dirt Cheap | ABBV | https://www.nasdaq.com/articles/this-warren-buffett-dividend-stock-is-still-dirt-cheap-2021-08-27 | null | null | Warren Buffett might not be as much of a value investor as he once was. However, he still likes to get a good bargain for the stocks added to Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) holdings.
The legendary investor also seems to prefer dividend stocks -- even though Berkshire itself has never paid a dividend. ... | A similar sales decline in the U.S. will be a big blow for AbbVie, since Humira generated more than 36% of its total revenue in the company's latest quarter. Reasons for optimism AbbVie President Mike Severino said in the Q2 conference call in July that the company remains confident that Rinvoq will win approvals in th... | AbbVie (NYSE: ABBV) is a Dividend Aristocrat with 49 consecutive years of dividend increases. Buffett's bargain Berkshire first scooped up shares of AbbVie in the third quarter of 2020. We don't know exactly when Berkshire first bought AbbVie stock during Q3 of 2020. | Behind AbbVie's low valuation Why is AbbVie stock so cheap? See the 10 stocks *Stock Advisor returns as of August 9, 2021 Keith Speights owns shares of AbbVie and Berkshire Hathaway (B shares). AbbVie (NYSE: ABBV) is a Dividend Aristocrat with 49 consecutive years of dividend increases. | We don't know exactly when Berkshire first bought AbbVie stock during Q3 of 2020. AbbVie (NYSE: ABBV) is a Dividend Aristocrat with 49 consecutive years of dividend increases. Buffett's bargain Berkshire first scooped up shares of AbbVie in the third quarter of 2020. |
23,957 | 2021-08-26 00:00:00 UTC | 3 Pharma Stocks to Buy With Juicy Dividends | ABBV | https://www.nasdaq.com/articles/3-pharma-stocks-to-buy-with-juicy-dividends-2021-08-26 | null | null | There are several industries and sectors that are known for their dividends. Utilities and real estate investment trusts definitely come to mind. But so does the pharmaceutical industry. Big pharma companies have been favorites for income investors for a long time.
We asked three Motley Fool contributors to pick pharma... | Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). Everything you'd want in a dividend stock Keith Speights (AbbVie): What do investors want in a dividend stock? AbbVie checks off all of these boxes. | See the 10 stocks *Stock Advisor returns as of August 9, 2021 Keith Speights owns shares of AbbVie and Pfizer. Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). Everything you'd want in a dividend stock Keith Speights (AbbVie): What do investors want in a dividend stock? | Everything you'd want in a dividend stock Keith Speights (AbbVie): What do investors want in a dividend stock? Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). AbbVie checks off all of these boxes. | Everything you'd want in a dividend stock Keith Speights (AbbVie): What do investors want in a dividend stock? Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). AbbVie checks off all of these boxes. |
23,958 | 2021-08-25 00:00:00 UTC | Is It Too Late to Buy Moderna Stock? | ABBV | https://www.nasdaq.com/articles/is-it-too-late-to-buy-moderna-stock-2021-08-25 | null | null | Some companies grow so fast for so long that it would have been impossible to overpay for shares at any point in their history. Admittedly, they are few and far between. Still, it's worth noting that truly transformational companies can always look overvalued and still be cheap. The hard part is finding them.
That's wh... | For context, the best-selling drug in the world in 2020 was Abbvie's Humira, at nearly $20 billion. Moderna raced out of the starting blocks, designing a vaccine only 48 hours after China published the genetic sequence of the SARS-CoV-2 virus on Jan. 11, 2020. Management already has agreements and options in place to s... | For context, the best-selling drug in the world in 2020 was Abbvie's Humira, at nearly $20 billion. As an exercise, we can map out the next few years and project some additional success with the other drug programs mentioned above. 2021 $20 billion* $13 billion 2022 $30 billion $20 billion 2023 $2 billion $1 billion 20... | For context, the best-selling drug in the world in 2020 was Abbvie's Humira, at nearly $20 billion. Cancer drugs make up about $100 billion of that total while vaccines -- before COVID -- were less than $50 billion. Moderna's influenza vaccine is only in phase 1 trials, but Sanofi sold about $2.9 billion worth last yea... | For context, the best-selling drug in the world in 2020 was Abbvie's Humira, at nearly $20 billion. That's what many are betting on with shares of Moderna (NASDAQ: MRNA). The opportunity for mRNA At this time last year, no country had ever approved a vaccine using mRNA. |
23,959 | 2021-08-24 00:00:00 UTC | 7 S&P 500 Stocks to Buy for Growth and Value | ABBV | https://www.nasdaq.com/articles/7-sp-500-stocks-to-buy-for-growth-and-value-2021-08-24 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
There’s nothing better than finding a great combination of growth and value in a stock. Unfortunately, it’s usually one or the other — a tradeoff depending on the situation. This tradeoff isn’t always the case though, and some S&P 500 stocks have a unique c... | AbbVie (NYSE:ABBV) Caesars (NASDAQ:CZR) Apple (NASDAQ:AAPL) Etsy (NASDAQ:ETSY) Gap (NYSE:GPS) Alphabet (NASDAQ:GOOGL, NASDAQ:GOOG) eBay (NASDAQ:EBAY) S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Leading off the charge is AbbVie. That leaves AbbVie stock trading less than 10 times earnings.... | AbbVie (NYSE:ABBV) Caesars (NASDAQ:CZR) Apple (NASDAQ:AAPL) Etsy (NASDAQ:ETSY) Gap (NYSE:GPS) Alphabet (NASDAQ:GOOGL, NASDAQ:GOOG) eBay (NASDAQ:EBAY) S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Leading off the charge is AbbVie. However, with estimates calling for roughly 20% earnings grow... | AbbVie (NYSE:ABBV) Caesars (NASDAQ:CZR) Apple (NASDAQ:AAPL) Etsy (NASDAQ:ETSY) Gap (NYSE:GPS) Alphabet (NASDAQ:GOOGL, NASDAQ:GOOG) eBay (NASDAQ:EBAY) S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Leading off the charge is AbbVie. That leaves AbbVie stock trading less than 10 times earnings.... | AbbVie (NYSE:ABBV) Caesars (NASDAQ:CZR) Apple (NASDAQ:AAPL) Etsy (NASDAQ:ETSY) Gap (NYSE:GPS) Alphabet (NASDAQ:GOOGL, NASDAQ:GOOG) eBay (NASDAQ:EBAY) S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Leading off the charge is AbbVie. That leaves AbbVie stock trading less than 10 times earnings.... |
23,960 | 2021-08-24 00:00:00 UTC | AbbVie Announces EC Approval Of RINVOQ In Treatment Of Moderate To Severe Atopic Dermatitis | ABBV | https://www.nasdaq.com/articles/abbvie-announces-ec-approval-of-rinvoq-in-treatment-of-moderate-to-severe-atopic | null | null | (RTTNews) - AbbVie (ABBV) said the European Commission has approved RINVOQ for the treatment of moderate to severe atopic dermatitis in adults and adolescents. The company noted that this marks the fourth EC-approved indication for RINVOQ.
RINVOQ is now approved in all member states of the European Union, as well as Ic... | (RTTNews) - AbbVie (ABBV) said the European Commission has approved RINVOQ for the treatment of moderate to severe atopic dermatitis in adults and adolescents. RINVOQ is now approved in all member states of the European Union, as well as Iceland, Liechtenstein, Norway and Northern Ireland. RINVOQ is a selective and rev... | (RTTNews) - AbbVie (ABBV) said the European Commission has approved RINVOQ for the treatment of moderate to severe atopic dermatitis in adults and adolescents. Phase 3 trials in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arterit... | (RTTNews) - AbbVie (ABBV) said the European Commission has approved RINVOQ for the treatment of moderate to severe atopic dermatitis in adults and adolescents. Phase 3 trials in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arterit... | (RTTNews) - AbbVie (ABBV) said the European Commission has approved RINVOQ for the treatment of moderate to severe atopic dermatitis in adults and adolescents. The company noted that this marks the fourth EC-approved indication for RINVOQ. RINVOQ is now approved in all member states of the European Union, as well as Ic... |
23,961 | 2021-08-21 00:00:00 UTC | 4 Reasons I Just Bought Ocular Therapeutix Stock | ABBV | https://www.nasdaq.com/articles/4-reasons-i-just-bought-ocular-therapeutix-stock-2021-08-21 | null | null | Shares of Ocular Therapeutix (NASDAQ: OCUL) have been hammered this year despite plenty of good reasons to expect rapid growth ahead. Now, the stock looks like a bargain opportunity poised to produce big gains for your portfolio.
This company's finding new ways to deliver well-understood drugs, which isn't the most int... | This is the active ingredient in Restasis, a prescription eye drop brand that generated $787 million in sales for AbbVie (NYSE: ABBV) last year. The company's current market cap of just $793 million, though, is just a little bit more than the amount of Restasis revenue AbbVie reported last year. In trials leading to it... | This is the active ingredient in Restasis, a prescription eye drop brand that generated $787 million in sales for AbbVie (NYSE: ABBV) last year. The company's current market cap of just $793 million, though, is just a little bit more than the amount of Restasis revenue AbbVie reported last year. In trials leading to it... | This is the active ingredient in Restasis, a prescription eye drop brand that generated $787 million in sales for AbbVie (NYSE: ABBV) last year. The company's current market cap of just $793 million, though, is just a little bit more than the amount of Restasis revenue AbbVie reported last year. Improving Dextenza sale... | This is the active ingredient in Restasis, a prescription eye drop brand that generated $787 million in sales for AbbVie (NYSE: ABBV) last year. The company's current market cap of just $793 million, though, is just a little bit more than the amount of Restasis revenue AbbVie reported last year. In July, Ocular Therape... |
23,962 | 2021-08-19 00:00:00 UTC | Why 180 Life Sciences Stock Is Falling Today | ABBV | https://www.nasdaq.com/articles/why-180-life-sciences-stock-is-falling-today-2021-08-19 | null | null | What happened
Shares of 180 Life Sciences (NASDAQ: ATNF), a clinical-stage drugmaker, are under pressure. Investors aren't happy because the company has announced the second dilutive capital raise since it completed a transaction with KBLM Merger Corp IV to gain its stock market listing last year. The stock was down 26... | AbbVie's mega-blockbuster is an anti-tumor necrosis factor (anti-TNF) injection used to treat rheumatoid arthritis, psoriasis, and a handful of less common inflammatory disorders. Instead, it has some new method-of-use patents regarding AbbVie's top-selling anti-inflammatory treatment, called Humira. The antibody itsel... | Instead, it has some new method-of-use patents regarding AbbVie's top-selling anti-inflammatory treatment, called Humira. AbbVie's mega-blockbuster is an anti-tumor necrosis factor (anti-TNF) injection used to treat rheumatoid arthritis, psoriasis, and a handful of less common inflammatory disorders. The antibody itsel... | Instead, it has some new method-of-use patents regarding AbbVie's top-selling anti-inflammatory treatment, called Humira. AbbVie's mega-blockbuster is an anti-tumor necrosis factor (anti-TNF) injection used to treat rheumatoid arthritis, psoriasis, and a handful of less common inflammatory disorders. The antibody itsel... | The antibody itself lost patent protection years ago and 180 Life Sciences has been able to patent methods of using it to treat rare inflammatory disorders that AbbVie probably never bothered with. Instead, it has some new method-of-use patents regarding AbbVie's top-selling anti-inflammatory treatment, called Humira. ... |
23,963 | 2021-08-18 00:00:00 UTC | Noteworthy ETF Inflows: VHT, ABBV, CVS, ANTM | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-vht-abbv-cvs-antm-2021-08-18 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $408.6 million dollar inflow -- that's a 2.5% increase week over week in outstanding units (from 61,717,573 to 63... | Among the largest underlying components of VHT, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.1%, CVS Health Corporation (Symbol: CVS) is off about 0.4%, and Anthem Inc (Symbol: ANTM) is lower by about 0.8%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year p... | Among the largest underlying components of VHT, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.1%, CVS Health Corporation (Symbol: CVS) is off about 0.4%, and Anthem Inc (Symbol: ANTM) is lower by about 0.8%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year p... | Among the largest underlying components of VHT, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.1%, CVS Health Corporation (Symbol: CVS) is off about 0.4%, and Anthem Inc (Symbol: ANTM) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... | Among the largest underlying components of VHT, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.1%, CVS Health Corporation (Symbol: CVS) is off about 0.4%, and Anthem Inc (Symbol: ANTM) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... |
23,964 | 2021-08-18 00:00:00 UTC | Like Dividends? I Bet You'll Love These 3 Stocks | ABBV | https://www.nasdaq.com/articles/like-dividends-i-bet-youll-love-these-3-stocks-2021-08-18 | null | null | There's no denying growth stocks can be a lot of fun to own, not to mention rewarding. There's also no denying, however, sometimes volatile growth names aren't always the best option for everyone. Many investors prefer the stability that only value-oriented equities can offer, and some investors need to live on reliabl... | AbbVie Current dividend yield: 4.5% It's possible you're more familiar with pharmaceutical maker AbbVie's (NYSE: ABBV) flagship drug than you are with the company itself. AbbVie is the name behind arthritis and Crohn's disease drug Humira, which accounted for more than 40% of the company's 2020 revenue of $45.8 billion... | AbbVie Current dividend yield: 4.5% It's possible you're more familiar with pharmaceutical maker AbbVie's (NYSE: ABBV) flagship drug than you are with the company itself. AbbVie is the name behind arthritis and Crohn's disease drug Humira, which accounted for more than 40% of the company's 2020 revenue of $45.8 billion... | AbbVie Current dividend yield: 4.5% It's possible you're more familiar with pharmaceutical maker AbbVie's (NYSE: ABBV) flagship drug than you are with the company itself. AbbVie is the name behind arthritis and Crohn's disease drug Humira, which accounted for more than 40% of the company's 2020 revenue of $45.8 billion... | AbbVie Current dividend yield: 4.5% It's possible you're more familiar with pharmaceutical maker AbbVie's (NYSE: ABBV) flagship drug than you are with the company itself. AbbVie is the name behind arthritis and Crohn's disease drug Humira, which accounted for more than 40% of the company's 2020 revenue of $45.8 billion... |
23,965 | 2021-08-17 00:00:00 UTC | Could AbbVie Stock Help You Retire a Millionaire? | ABBV | https://www.nasdaq.com/articles/could-abbvie-stock-help-you-retire-a-millionaire-2021-08-17 | null | null | When it comes to planning for your financial future, it pays to pack your portfolio with stocks that can keep growing even if the market is falling. Though there's no shortcut to riches, with prudent investments, you can definitely get a lot closer than you might otherwise, provided that you have enough time to let you... | While there are a lot of factors that can make a stock go up, in AbbVie's case you can look forward to catalysts like drugs advancing through the clinical trials process and getting regulatory approval for sale. Each of AbbVie's pipeline programs represents only a small slice of its potential future revenue, so each ne... | It isn't about to make you millions on its own As beneficial as buying AbbVie stock could be, don't expect it to make you rich. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Alex Carchidi owns shares of AbbVie and Abbott Laboratories. In this vein, drugmaker AbbVie (NYSE: ABBV) might be a strong contender... | Owning this stock will probably make you richer There are a few ways that buying and holding AbbVie's stock will bolster your portfolio's value in the long term. It isn't about to make you millions on its own As beneficial as buying AbbVie stock could be, don't expect it to make you rich. See the 10 stocks *Stock Advis... | It isn't about to make you millions on its own As beneficial as buying AbbVie stock could be, don't expect it to make you rich. In this vein, drugmaker AbbVie (NYSE: ABBV) might be a strong contender for the part of your portfolio that's devoted to stable, stalwart stocks. Owning this stock will probably make you riche... |
23,966 | 2021-08-17 00:00:00 UTC | 3 Top Biotech Stocks to Buy in August | ABBV | https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-in-august-2021-08-17 | null | null | As investors, it benefits us to pay attention to trends -- particularly those massive trends that have been under way for some time and that are likely to continue.
Arguably one of the best examples is what demographers refer to as the "grey tsunami," which is a term for the large wave of baby boomers in the U.S. who h... | According to Vice Chairman Mike Severino, AbbVie remains on track to submit regulatory applications to the U.S. Food and Drug Administration (FDA) later this year for Rinvoq in ulcerative colitis and Skyrizi in Crohn's disease. These demographic developments therefore matter very much to healthcare companies such as Ab... | These demographic developments therefore matter very much to healthcare companies such as AbbVie (NYSE: ABBV), AstraZeneca (NASDAQ: AZN), and Viatris, (NASDAQ: VTRS), all of which I believe are reasonably valued picks for August. AbbVie Pharma stock AbbVie has been working very diligently over the past few years to dev... | AbbVie Pharma stock AbbVie has been working very diligently over the past few years to develop its next blockbuster drugs that will offset its loss of exclusivity for the top-selling drug in the world, immunology wonder drug Humira. These demographic developments therefore matter very much to healthcare companies such ... | AbbVie Pharma stock AbbVie has been working very diligently over the past few years to develop its next blockbuster drugs that will offset its loss of exclusivity for the top-selling drug in the world, immunology wonder drug Humira. These demographic developments therefore matter very much to healthcare companies such ... |
23,967 | 2021-08-16 00:00:00 UTC | Buffett's Berkshire pares drug holdings, sheds Axalta, Biogen | ABBV | https://www.nasdaq.com/articles/buffetts-berkshire-pares-drug-holdings-sheds-axalta-biogen-2021-08-16 | null | null | By Jonathan Stempel
Aug 16 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co MRK.N spinoff, Organon & Co OGN.N.
In the second quarter, Berkshire said it exited a $180 million s... | In the second quarter, Berkshire said it exited a $180 million stake in Biogen Inc BIIB.O and reduced investments in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N and Merck. That suggests Buffett and his investment managers Todd Combs and Ted Weschler remain wary of valuations as stock prices regularly set new highs... | In the second quarter, Berkshire said it exited a $180 million stake in Biogen Inc BIIB.O and reduced investments in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N and Merck. By Jonathan Stempel Aug 16 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it trimmed or eliminated its stakes in sev... | In the second quarter, Berkshire said it exited a $180 million stake in Biogen Inc BIIB.O and reduced investments in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N and Merck. By Jonathan Stempel Aug 16 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it trimmed or eliminated its stakes in sev... | In the second quarter, Berkshire said it exited a $180 million stake in Biogen Inc BIIB.O and reduced investments in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N and Merck. By Jonathan Stempel Aug 16 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it trimmed or eliminated its stakes in sev... |
23,968 | 2021-08-13 00:00:00 UTC | What Rinvoq's Positive News Means for AbbVie | ABBV | https://www.nasdaq.com/articles/what-rinvoqs-positive-news-means-for-abbvie-2021-08-13 | null | null | On Aug. 4, pharmaceutical giant AbbVie (NYSE: ABBV) reported encouraging results from a phase 3b study of adults with a chronic skin disease known as moderate to severe atopic dermatitis or eczema.
The study pitted AbbVie's JAK inhibitor Rinvoq against Dupixent, a joint effort between Sanofi (NASDAQ: SNY) and Regeneron... | On Aug. 4, pharmaceutical giant AbbVie (NYSE: ABBV) reported encouraging results from a phase 3b study of adults with a chronic skin disease known as moderate to severe atopic dermatitis or eczema. At just 10.3 times its trailing-12-month free cash flow, AbbVie is trading well below its median historical price to FCF r... | Assuming that 40% of atopic dermatitis cases globally are moderate to severe, AbbVie's potential addressable market would grow from $4.7 billion in 2021 to $8.7 billion by 2026.If we assume it can achieve an 8% market share in moderate to severe atopic dermatitis (Dupixent has been able to embed itself firmly in the ma... | Rinvoq beats the industry leader in a late-stage head-to-head study Rinvoq achieved superiority compared to Dupixent for the trial's primary endpoint, meaning the former drug reported a higher number of patients with at least a 75% improvement in the Eczema Area and Severity Index (EASI 75) at week 16, according to Abb... | On Aug. 4, pharmaceutical giant AbbVie (NYSE: ABBV) reported encouraging results from a phase 3b study of adults with a chronic skin disease known as moderate to severe atopic dermatitis or eczema. Assuming that 40% of atopic dermatitis cases globally are moderate to severe, AbbVie's potential addressable market would ... |
23,969 | 2021-08-12 00:00:00 UTC | Best Biotech Stocks To Watch In 2021? 4 To Know | ABBV | https://www.nasdaq.com/articles/best-biotech-stocks-to-watch-in-2021-4-to-know-2021-08-12 | null | null | Do You Have These Top Biotech Stocks On Your Radar Today?
With the global pandemic raging on, biotech stocks have and continue to take center stage in the stock market today. This would be the case since Pfizer’s (NYSE: PFE) and BioNTech’s (NASDAQ: BNTX) initial coronavirus vaccine breakthrough late last year. Not only... | Best Biotech Stocks To Buy [Or Avoid] Now Crispr Therapeutics (NASDAQ: CRSP) Cassava Sciences Inc. (NASDAQ: SAVA) AbbVie Inc. (NYSE: ABBV) C4 Therapeutics Inc. (NASDAQ: CCCC) CRISPR Therapeutics AG CRISPR Therapeutics is a biotech company with headquarters in Zug, Switzerland. 4 E-Commerce Stocks To Know AbbVie Inc. Ab... | Best Biotech Stocks To Buy [Or Avoid] Now Crispr Therapeutics (NASDAQ: CRSP) Cassava Sciences Inc. (NASDAQ: SAVA) AbbVie Inc. (NYSE: ABBV) C4 Therapeutics Inc. (NASDAQ: CCCC) CRISPR Therapeutics AG CRISPR Therapeutics is a biotech company with headquarters in Zug, Switzerland. 4 E-Commerce Stocks To Know AbbVie Inc. Ab... | Best Biotech Stocks To Buy [Or Avoid] Now Crispr Therapeutics (NASDAQ: CRSP) Cassava Sciences Inc. (NASDAQ: SAVA) AbbVie Inc. (NYSE: ABBV) C4 Therapeutics Inc. (NASDAQ: CCCC) CRISPR Therapeutics AG CRISPR Therapeutics is a biotech company with headquarters in Zug, Switzerland. 4 E-Commerce Stocks To Know AbbVie Inc. Ab... | Best Biotech Stocks To Buy [Or Avoid] Now Crispr Therapeutics (NASDAQ: CRSP) Cassava Sciences Inc. (NASDAQ: SAVA) AbbVie Inc. (NYSE: ABBV) C4 Therapeutics Inc. (NASDAQ: CCCC) CRISPR Therapeutics AG CRISPR Therapeutics is a biotech company with headquarters in Zug, Switzerland. 4 E-Commerce Stocks To Know AbbVie Inc. Ab... |
23,970 | 2021-08-11 00:00:00 UTC | After Hours Most Active for Aug 11, 2021 : CLOV, HBAN, CVE, QQQ, ACWI, CLF, MDLZ, KBWB, MTG, MFC, ABBV, LXP | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-for-aug-11-2021-%3A-clov-hban-cve-qqq-acwi-clf-mdlz-kbwb-mtg-mfc | null | null | The NASDAQ 100 After Hours Indicator is down -6.14 to 15,021.62. The total After hours volume is currently 74,890,420 shares traded.
The following are the most active stocks for the after hours session:
Clover Health Investments, Corp. (CLOV) is +0.57 at $8.70, with 6,577,492 shares traded. CLOV's current last sale i... | AbbVie Inc. (ABBV) is +0.09 at $113.81, with 1,594,062 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2021. | AbbVie Inc. (ABBV) is +0.09 at $113.81, with 1,594,062 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2021. | AbbVie Inc. (ABBV) is +0.09 at $113.81, with 1,594,062 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2021. | AbbVie Inc. (ABBV) is +0.09 at $113.81, with 1,594,062 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The NASDAQ 100 After Hours Indicator is down -6.14 to 15,021.62. |
23,971 | 2021-08-11 00:00:00 UTC | Forget Robinhood, These 3 Healthcare Stocks Are Better Buys | ABBV | https://www.nasdaq.com/articles/forget-robinhood-these-3-healthcare-stocks-are-better-buys-2021-08-11 | null | null | Mostfinancial newsisn't created with the purpose of producing good investment decisions. It is designed to provide information in an engaging way while creating a constant sense of needing to act. This year offers plenty of examples. The latest is the recent initial public offering of Robinhood Markets (NASDAQ: HOOD), ... | While Humira will relinquish its U.S. patent exclusivity in 2023, its authority as an established brand name and longstanding status as the best-selling drug in the world should continue to drive notable revenue growth for AbbVie. From its healthy track record of balance sheet growth to its impressive portfolio of bran... | They chose Inari Medical (NASDAQ: NARI), AbbVie (NYSE: ABBV), and Illumina (NASDAQ: ILMN). A superior dividend play Rachel Warren (AbbVie): If you're searching for a stock that can yield consistent, generous returns for your portfolio, AbbVie is another no-brainer pick to add to your buy basket. AbbVie, which was spun ... | They chose Inari Medical (NASDAQ: NARI), AbbVie (NYSE: ABBV), and Illumina (NASDAQ: ILMN). A superior dividend play Rachel Warren (AbbVie): If you're searching for a stock that can yield consistent, generous returns for your portfolio, AbbVie is another no-brainer pick to add to your buy basket. AbbVie, which was spun ... | AbbVie's mega-blockbuster drug Humira has remained the top-selling product in its portfolio year after year, amassing billions upon billions of dollars in annual revenue. They chose Inari Medical (NASDAQ: NARI), AbbVie (NYSE: ABBV), and Illumina (NASDAQ: ILMN). A superior dividend play Rachel Warren (AbbVie): If you're... |
23,972 | 2021-08-10 00:00:00 UTC | 3 Key Takeaways From AbbVie's Second-Quarter Earnings | ABBV | https://www.nasdaq.com/articles/3-key-takeaways-from-abbvies-second-quarter-earnings-2021-08-10 | null | null | The last week of July was a busy one for investors, with several big-name companies releasing their quarterly updates for the period ending on June 30. One of those was pharma giant AbbVie (NYSE: ABBV), and the drugmaker's results were impressive.
AbbVie recorded total revenue of roughly $14 billion, 19.3% higher than ... | Passing of the torch AbbVie's reliance on Humira would be a major problem if it weren't for the fact that the company devised a careful plan to decrease its top-line dependence on this drug. Regarding these two drugs, AbbVie's CEO Richard Gonzalez said the following during the company's second-quarterearnings conferenc... | AbbVie recorded total revenue of roughly $14 billion, 19.3% higher than the year-ago period on an operational basis. Humira's U.S. revenue is still growing International sales of AbbVie's blockbuster rheumatoid arthritis medicine Humira have been declining since it lost patent exclusivity in Europe in 2018. One of thos... | Humira's U.S. revenue is still growing International sales of AbbVie's blockbuster rheumatoid arthritis medicine Humira have been declining since it lost patent exclusivity in Europe in 2018. And with growing revenue and earnings, as well as one of the safest dividends around, AbbVie's stock still looks like a buy, esp... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! One of those was pharma giant AbbVie (NYSE: ABBV), and the drugmaker's results were impressive. AbbVie recorded total revenue of roughly $14 billion, 19.3% higher than the year-ago period on a... |
23,973 | 2021-08-09 00:00:00 UTC | AbbVie Launches SKYRIZI As Single-dose 150 Mg Injection - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-launches-skyrizi-as-single-dose-150-mg-injection-quick-facts-2021-08-09 | null | null | (RTTNews) - AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis. The new SKYRIZI 150 mg pen comes with audible cues to help guide the administration process and an indicator... | (RTTNews) - AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis. AbbVie noted that SKYRIZI is part of a collaboration with Boehringer Ingelheim, with the company leading dev... | (RTTNews) - AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis. AbbVie noted that SKYRIZI is part of a collaboration with Boehringer Ingelheim, with the company leading dev... | (RTTNews) - AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis. AbbVie noted that SKYRIZI is part of a collaboration with Boehringer Ingelheim, with the company leading dev... | (RTTNews) - AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis. AbbVie noted that SKYRIZI is part of a collaboration with Boehringer Ingelheim, with the company leading dev... |
23,974 | 2021-08-08 00:00:00 UTC | Here Are the 12 Best Dividend Stocks I Own Right Now | ABBV | https://www.nasdaq.com/articles/here-are-the-12-best-dividend-stocks-i-own-right-now-2021-08-08 | null | null | Some investors concentrate their portfolios on just a handful of stocks. I like too many businesses to limit my choices. As a result, my portfolio is rather large -- typically between 40 and 50 stocks.
While many of these are growth stocks that don't pay dividends, quite a few of my holdings do. Here are the 12 best di... | AbbVie (NYSE: ABBV) 4.5% Bristol Myers Squibb (NYSE: BMY) 2.9% Pfizer (NYSE: PFE) 3.5% You won't find many better dividend stocks than AbbVie. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Air Products & Chemicals, Bristol Myers Squibb, Brookfield Infrastructure Corpo... | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Air Products & Chemicals, Bristol Myers Squibb, Brookfield Infrastructure Corporation, Brookfield Infrastructure Partners, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., Chevron, Enterprise Prod... | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Air Products & Chemicals, Bristol Myers Squibb, Brookfield Infrastructure Corporation, Brookfield Infrastructure Partners, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., Chevron, Enterprise Prod... | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Air Products & Chemicals, Bristol Myers Squibb, Brookfield Infrastructure Corporation, Brookfield Infrastructure Partners, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., Chevron, Enterprise Prod... |
23,975 | 2021-08-06 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-2021-08-06 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Cardinal Health, Inc. (Symbol: CAH) $50.57 $61.20 21.02% Cincinnati Financial Corp. (Symbol: CINF) $116.39 $124.50 6.97% AbbVie Inc (Symbol: ABBV) $115.12 $123.08 6.91% Kimberly-Clark Corp. (Symbol: KMB) $133.41 $141.45 6.03% PepsiCo Inc (Symbol: PEP) $154.31 $162.77 5.48% The average 12-month analyst targets are only ... | Cardinal Health, Inc. (Symbol: CAH) $50.57 $61.20 21.02% Cincinnati Financial Corp. (Symbol: CINF) $116.39 $124.50 6.97% AbbVie Inc (Symbol: ABBV) $115.12 $123.08 6.91% Kimberly-Clark Corp. (Symbol: KMB) $133.41 $141.45 6.03% PepsiCo Inc (Symbol: PEP) $154.31 $162.77 5.48% The average 12-month analyst targets are only ... | Cardinal Health, Inc. (Symbol: CAH) $50.57 $61.20 21.02% Cincinnati Financial Corp. (Symbol: CINF) $116.39 $124.50 6.97% AbbVie Inc (Symbol: ABBV) $115.12 $123.08 6.91% Kimberly-Clark Corp. (Symbol: KMB) $133.41 $141.45 6.03% PepsiCo Inc (Symbol: PEP) $154.31 $162.77 5.48% The average 12-month analyst targets are only ... | Cardinal Health, Inc. (Symbol: CAH) $50.57 $61.20 21.02% Cincinnati Financial Corp. (Symbol: CINF) $116.39 $124.50 6.97% AbbVie Inc (Symbol: ABBV) $115.12 $123.08 6.91% Kimberly-Clark Corp. (Symbol: KMB) $133.41 $141.45 6.03% PepsiCo Inc (Symbol: PEP) $154.31 $162.77 5.48% The average 12-month analyst targets are only ... |
23,976 | 2021-08-04 00:00:00 UTC | Why AbbVie is a Top Socially Responsible Dividend Stock (ABBV) | ABBV | https://www.nasdaq.com/articles/why-abbvie-is-a-top-socially-responsible-dividend-stock-abbv-2021-08-04 | null | null | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.5% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.5% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.5% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.5% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.5% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... |
23,977 | 2021-08-04 00:00:00 UTC | 1 Major Takeaway From Pfizer's Blowout Second-Quarter Results | ABBV | https://www.nasdaq.com/articles/1-major-takeaway-from-pfizers-blowout-second-quarter-results-2021-08-04 | null | null | Pharma giant Pfizer (NYSE: PFE) released its second-quarter earnings report on July 28, and the results were impressive. Naturally, the big story surrounded the drugmaker's COVID-19 vaccine, BNT162b2, whose revenue came in at $7.8 billion for the period. BNT162b2 is the gift that keeps on giving, and Pfizer now expects... | The study pitted the RA medicine against TNF-inhibitors, a class of drugs that treat autoimmune disorders; this group includes AbbVie's Humira. Other avenues for growth In the worst-case scenario, the FDA would take Xeljanz off the market on the grounds that the medicine's risks far outweigh its benefits. Why you may w... | The study pitted the RA medicine against TNF-inhibitors, a class of drugs that treat autoimmune disorders; this group includes AbbVie's Humira. Declining sales of Xeljanz Xeljanz, a medicine indicated for the treatment of rheumatoid arthritis (RA) and plaque psoriasis, is often touted as a key growth driver for Pfizer.... | The study pitted the RA medicine against TNF-inhibitors, a class of drugs that treat autoimmune disorders; this group includes AbbVie's Humira. BNT162b2 is the gift that keeps on giving, and Pfizer now expects total revenue of $33.5 billion from the vaccine this year, which is up from its previous guidance of $26 billi... | The study pitted the RA medicine against TNF-inhibitors, a class of drugs that treat autoimmune disorders; this group includes AbbVie's Humira. In January, Pfizer reported results from a post-marketing study for Xeljanz. Putting aside revenue from BNT162b2, first-quarter revenue of $11.1 billion was up 10% compared to ... |
23,978 | 2021-08-04 00:00:00 UTC | How This Historic FDA Approval Benefits Viatris | ABBV | https://www.nasdaq.com/articles/how-this-historic-fda-approval-benefits-viatris-2021-08-04 | null | null | U.S. biopharmaceutical company Viatris (NASDAQ: VTRS) and its partner, Indian biopharma Biocon, announced on July 28 that the U.S. Food and Drug Administration (FDA) had approved their biosimilar insulin drug, Semglee, as an "interchangeable biosimilar" -- a direct alternative to Sanofi's (NASDAQ: SNY) blockbuster insu... | Viatris also has a number of biosimilar products in the pipeline, including one for AbbVie's (NYSE: ABBV) aesthetics and neuroscience blockbuster drug Botox that's it's currently developing with Revance Therapeutics (NASDAQ: RVNC), and another partnership with Biocon on a biosimilar for Sanofi's insulin drug Toujeo (th... | Viatris also has a number of biosimilar products in the pipeline, including one for AbbVie's (NYSE: ABBV) aesthetics and neuroscience blockbuster drug Botox that's it's currently developing with Revance Therapeutics (NASDAQ: RVNC), and another partnership with Biocon on a biosimilar for Sanofi's insulin drug Toujeo (th... | Viatris also has a number of biosimilar products in the pipeline, including one for AbbVie's (NYSE: ABBV) aesthetics and neuroscience blockbuster drug Botox that's it's currently developing with Revance Therapeutics (NASDAQ: RVNC), and another partnership with Biocon on a biosimilar for Sanofi's insulin drug Toujeo (th... | Viatris also has a number of biosimilar products in the pipeline, including one for AbbVie's (NYSE: ABBV) aesthetics and neuroscience blockbuster drug Botox that's it's currently developing with Revance Therapeutics (NASDAQ: RVNC), and another partnership with Biocon on a biosimilar for Sanofi's insulin drug Toujeo (th... |
23,979 | 2021-08-04 00:00:00 UTC | $5,000 Invested in These 3 Healthcare Stocks Could Make You Rich Over the Next 10 Years | ABBV | https://www.nasdaq.com/articles/%245000-invested-in-these-3-healthcare-stocks-could-make-you-rich-over-the-next-10-years | null | null | Healthcare has undergone massive changes in the past decade. A global pandemic will overshadow much of it in the eyes of history, but legislation, reimbursement changes, and scientific breakthroughs permeated the 2010s. It probably leaves investors wondering what the next decade has in store.
No one can predict the fut... | Just last year, Gilead Sciences bought Forty Seven for $4.9 billion and AbbVie inked a deal with Chinese biotech I-Mab that could be worth as much as $2 billion. From work to school to social activities, people turned to virtual options to facilitate these essential needs when stay-at-home orders forced much of the wor... | Just last year, Gilead Sciences bought Forty Seven for $4.9 billion and AbbVie inked a deal with Chinese biotech I-Mab that could be worth as much as $2 billion. A challenger in the sequencing market Steve Ditto (Pacific Biosciences of California): Pacific Biosciences of California, known as PacBio, is developing its H... | Just last year, Gilead Sciences bought Forty Seven for $4.9 billion and AbbVie inked a deal with Chinese biotech I-Mab that could be worth as much as $2 billion. Given Teladoc's fantastic track record of growth, continued successes throughout the pandemic, and rosy financial expectations -- the company is projecting ab... | Just last year, Gilead Sciences bought Forty Seven for $4.9 billion and AbbVie inked a deal with Chinese biotech I-Mab that could be worth as much as $2 billion. CEO Jan Skvarka said its drugs have shown "substantial" anti-tumor activity and have given management a "strong basis" for testing it in solid tumors. ARK exi... |
23,980 | 2021-08-02 00:00:00 UTC | Abbott's Subsidiaries Agree To Pay $160 Mln To Settle Alleged False Claims To Medicare | ABBV | https://www.nasdaq.com/articles/abbotts-subsidiaries-agree-to-pay-%24160-mln-to-settle-alleged-false-claims-to-medicare-2021 | null | null | (RTTNews) - Arriva Medical LLC and its parent Alere Inc have agreed to pay $160 million to settle allegations that they made, or caused, claims to Medicare that were false because kickbacks were paid to Medicare beneficiaries, patients were ineligible to receive meters, or patients were deceased, the U.S. Department of... | (RTTNews) - Arriva Medical LLC and its parent Alere Inc have agreed to pay $160 million to settle allegations that they made, or caused, claims to Medicare that were false because kickbacks were paid to Medicare beneficiaries, patients were ineligible to receive meters, or patients were deceased, the U.S. Department of... | (RTTNews) - Arriva Medical LLC and its parent Alere Inc have agreed to pay $160 million to settle allegations that they made, or caused, claims to Medicare that were false because kickbacks were paid to Medicare beneficiaries, patients were ineligible to receive meters, or patients were deceased, the U.S. Department of... | (RTTNews) - Arriva Medical LLC and its parent Alere Inc have agreed to pay $160 million to settle allegations that they made, or caused, claims to Medicare that were false because kickbacks were paid to Medicare beneficiaries, patients were ineligible to receive meters, or patients were deceased, the U.S. Department of... | Until it ceased business operations in December 2017, Arriva was a mail-order diabetic testing supply company based in Coral Springs, Florida. The United States alleged that, from April 2010 until the end of 2016, Arriva, with Alere's approval, paid kickbacks to Medicare beneficiaries by providing them "free" or "no co... |
23,981 | 2021-08-02 00:00:00 UTC | After Hours Most Active for Aug 2, 2021 : EDU, ABEV, CD, STRA, UBER, AAPL, ABBV, LUMN, CLF, AZN, LBTYK, XLNX | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-for-aug-2-2021-%3A-edu-abev-cd-stra-uber-aapl-abbv-lumn-clf-azn | null | null | The NASDAQ 100 After Hours Indicator is down -4.59 to 14,959.03. The total After hours volume is currently 59,070,607 shares traded.
The following are the most active stocks for the after hours session:
New Oriental Education & Technology Group, Inc. (EDU) is unchanged at $2.17, with 23,194,644 shares traded.EDU is s... | AbbVie Inc. (ABBV) is unchanged at $115.45, with 1,856,028 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". New Oriental Education & Technology Group, Inc. (EDU) is unchanged at $2.17, with 23,194,644 shares traded.EDU is scheduled to provide an earnings report on 8/3... | AbbVie Inc. (ABBV) is unchanged at $115.45, with 1,856,028 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". New Oriental Education & Technology Group, Inc. (EDU) is unchanged at $2.17, with 23,194,644 shares traded.EDU is scheduled to provide an earnings report on 8/3... | AbbVie Inc. (ABBV) is unchanged at $115.45, with 1,856,028 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". New Oriental Education & Technology Group, Inc. (EDU) is unchanged at $2.17, with 23,194,644 shares traded.EDU is scheduled to provide an earnings report on 8/3... | AbbVie Inc. (ABBV) is unchanged at $115.45, with 1,856,028 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". Over the last four weeks they have had 7 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2021. |
23,982 | 2021-08-01 00:00:00 UTC | Takeda to record 63 bln yen provision, update Q1 results on Irish tax issue | ABBV | https://www.nasdaq.com/articles/takeda-to-record-63-bln-yen-provision-update-q1-results-on-irish-tax-issue-2021-08-02 | null | null | Aug 2 (Reuters) - Takeda Pharmaceutical Co 4502.T said on Monday it will record a provision of about 63 billion yen ($574.56 million) in its financial statements for the first quarter to reflect a decision by Ireland's tax appeals body relating to tax assessment received by company's unit on a break fee.
Takeda said it... | Takeda said it received "a decision by the Irish Tax Appeals Commission on July 30, 2021 to uphold the Irish Revenue Commissioners' position related to the treatment of a break fee received by Shire plc in October 2014 from AbbVie Inc,". Shire Plc, which Takeda acquired in 2019, received a tax assessment from the Irish... | Shire Plc, which Takeda acquired in 2019, received a tax assessment from the Irish Revenue Commissioners to tax a break fee the company received from AbbVie Inc ABBV.N for terminating its offer to acquire Shire. Takeda said it received "a decision by the Irish Tax Appeals Commission on July 30, 2021 to uphold the Irish... | Takeda said it received "a decision by the Irish Tax Appeals Commission on July 30, 2021 to uphold the Irish Revenue Commissioners' position related to the treatment of a break fee received by Shire plc in October 2014 from AbbVie Inc,". Shire Plc, which Takeda acquired in 2019, received a tax assessment from the Irish... | Shire Plc, which Takeda acquired in 2019, received a tax assessment from the Irish Revenue Commissioners to tax a break fee the company received from AbbVie Inc ABBV.N for terminating its offer to acquire Shire. Takeda said it received "a decision by the Irish Tax Appeals Commission on July 30, 2021 to uphold the Irish... |
23,983 | 2021-08-01 00:00:00 UTC | 3 Underrated Warren Buffett Stocks That Are Smart Buys Right Now | ABBV | https://www.nasdaq.com/articles/3-underrated-warren-buffett-stocks-that-are-smart-buys-right-now-2021-08-01 | null | null | You might think that any stock handpicked by Warren Buffett and his top investment managers would be held in high regard by most investors. However, that's not necessarily the case.
Several stocks in Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) portfolio are either beaten down, have bargain valuations, or both. But... | AbbVie The average pharmaceutical stock in the S&P 500 trades at more than 14 times expected earnings. That context is important to understand just how cheap AbbVie (NYSE: ABBV) is with its shares trading below 9.5 times expected earnings. AbbVie was one of several big pharma stocks that Buffett scooped up for Berkshir... | AbbVie The average pharmaceutical stock in the S&P 500 trades at more than 14 times expected earnings. That context is important to understand just how cheap AbbVie (NYSE: ABBV) is with its shares trading below 9.5 times expected earnings. AbbVie was one of several big pharma stocks that Buffett scooped up for Berkshir... | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie and Berkshire Hathaway (B shares). AbbVie The average pharmaceutical stock in the S&P 500 trades at more than 14 times expected earnings. That context is important to understand just how cheap AbbVie (NYSE: ABBV) is with it... | AbbVie The average pharmaceutical stock in the S&P 500 trades at more than 14 times expected earnings. That context is important to understand just how cheap AbbVie (NYSE: ABBV) is with its shares trading below 9.5 times expected earnings. AbbVie was one of several big pharma stocks that Buffett scooped up for Berkshir... |
23,984 | 2021-07-31 00:00:00 UTC | AbbVie (ABBV) Q2 2021 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q2-2021-earnings-call-transcript-2021-07-31 | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q2 2021 Earnings Call
Jul 30, 2021, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning. Thank you for standing by, and welcome to the AbbVie second-quarter 2021earnings conference call [Operator inst... | AbbVie (NYSE: ABBV) Q2 2021 Earnings Call Jul 30, 2021, 9:00 a.m. Thank you for standing by, and welcome to the AbbVie second-quarter 2021earnings conference call [Operator instructions] I would now like to introduce Ms. Liz Shea, vice president of investor relations. AbbVie cautions that these forward-looking statemen... | Operator [Operator signoff] Duration: 85 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Mike Severino -- Vice Chairman and President Rob Michael -- Executive Vi... | Operator [Operator signoff] Duration: 85 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Mike Severino -- Vice Chairman and President Rob Michael -- Executive Vi... | skyrizi and rinvoq continue to have significant impact on AbbVie's growth and performance, contributing more than $1 billion in combined sales this quarter. Operator [Operator signoff] Duration: 85 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chi... |
23,985 | 2021-07-30 00:00:00 UTC | Health Care Sector Update for 07/30/2021: ERYP, FMS, ABBV, XLV, IBB | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-07-30-2021%3A-eryp-fms-abbv-xlv-ibb-2021-07-30 | null | null | Health care stocks were mixed pre-bell Friday. The Health Care SPDR (XLV) was slipping by 0.14% and the iShares NASDAQ Biotechnology Index (IBB) was recently inactive
Erytech Pharma (ERYP) was surging past 98% after saying the Food and Drug Administration has granted fast track designation to eryaspase for the treatmen... | AbbVie (ABBV) was marginally advancing as it posted Q2 adjusted earnings of $3.11 per share, up from $2.34 per share a year earlier. Health care stocks were mixed pre-bell Friday. The Health Care SPDR (XLV) was slipping by 0.14% and the iShares NASDAQ Biotechnology Index (IBB) was recently inactive Erytech Pharma (ERYP... | AbbVie (ABBV) was marginally advancing as it posted Q2 adjusted earnings of $3.11 per share, up from $2.34 per share a year earlier. Health care stocks were mixed pre-bell Friday. Fresenius Medical Care (FMS) was down more than 2% as it reported adjusted earnings of 0.76 euros ($0.90) per share in Q2, down from 1.20 eu... | AbbVie (ABBV) was marginally advancing as it posted Q2 adjusted earnings of $3.11 per share, up from $2.34 per share a year earlier. The Health Care SPDR (XLV) was slipping by 0.14% and the iShares NASDAQ Biotechnology Index (IBB) was recently inactive Erytech Pharma (ERYP) was surging past 98% after saying the Food an... | AbbVie (ABBV) was marginally advancing as it posted Q2 adjusted earnings of $3.11 per share, up from $2.34 per share a year earlier. Health care stocks were mixed pre-bell Friday. The Health Care SPDR (XLV) was slipping by 0.14% and the iShares NASDAQ Biotechnology Index (IBB) was recently inactive Erytech Pharma (ERYP... |
23,986 | 2021-07-30 00:00:00 UTC | Have $500? Here Are 2 High-Yielding Healthcare Stocks to Consider | ABBV | https://www.nasdaq.com/articles/have-%24500-here-are-2-high-yielding-healthcare-stocks-to-consider-2021-07-30 | null | null | The markets have surged since the COVID-induced panic of last February and March, with recent rollbacks of coronavirus-related public health guidelines boosting the economy in many areas. But this upward trajectory in financial markets, coupled with low, risk-free rates offered by bonds, has left income investors with ... | AbbVie AbbVie (NYSE: ABBV) is a diversified biotech company with a 4.4% yield. The good news for AbbVie is that the company is more than ready to make up for Humira's revenue declines with its other two blockbuster immunology drugs, Rinvoq and Skyrizi. AbbVie's revenue from Skyrizi also showed significant growth, nearl... | Third, AbbVie's adjusted earnings per share (EPS) payout ratio leaves the company with a secure payout. AbbVie and Pfizer, meanwhile, offer investors more than triple the S&P's average yield and improving fundamentals, decent-to-robust balance sheets, and sustainable payout ratios in the 40% range. AbbVie AbbVie (NYSE:... | AbbVie AbbVie (NYSE: ABBV) is a diversified biotech company with a 4.4% yield. The good news for AbbVie is that the company is more than ready to make up for Humira's revenue declines with its other two blockbuster immunology drugs, Rinvoq and Skyrizi. AbbVie's revenue from Skyrizi also showed significant growth, nearl... | AbbVie and Pfizer, meanwhile, offer investors more than triple the S&P's average yield and improving fundamentals, decent-to-robust balance sheets, and sustainable payout ratios in the 40% range. AbbVie AbbVie (NYSE: ABBV) is a diversified biotech company with a 4.4% yield. The good news for AbbVie is that the company ... |
23,987 | 2021-07-30 00:00:00 UTC | AbbVie raises annual profit forecast as Botox demand rebounds | ABBV | https://www.nasdaq.com/articles/abbvie-raises-annual-profit-forecast-as-botox-demand-rebounds-2021-07-30-0 | null | null | Compares with estimates, adds analyst comment
July 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N raised its 2021 adjusted profit forecast on Friday, betting that a demand uptick for its Botox anti-wrinkle injection due to easing lockdowns will help overcome weak international sales for blockbuster drug Humira.
Sales of Bo... | Compares with estimates, adds analyst comment July 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N raised its 2021 adjusted profit forecast on Friday, betting that a demand uptick for its Botox anti-wrinkle injection due to easing lockdowns will help overcome weak international sales for blockbuster drug Humira. The strong ... | Compares with estimates, adds analyst comment July 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N raised its 2021 adjusted profit forecast on Friday, betting that a demand uptick for its Botox anti-wrinkle injection due to easing lockdowns will help overcome weak international sales for blockbuster drug Humira. The strong ... | Compares with estimates, adds analyst comment July 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N raised its 2021 adjusted profit forecast on Friday, betting that a demand uptick for its Botox anti-wrinkle injection due to easing lockdowns will help overcome weak international sales for blockbuster drug Humira. AbbVie said... | AbbVie said it expects full-year adjusted earnings between $12.52 and $12.62 per share, compared with $12.37 to $12.57 per share previously. Compares with estimates, adds analyst comment July 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N raised its 2021 adjusted profit forecast on Friday, betting that a demand uptick for ... |
23,988 | 2021-07-30 00:00:00 UTC | AbbVie raises annual profit forecast as Botox demand rebounds | ABBV | https://www.nasdaq.com/articles/abbvie-raises-annual-profit-forecast-as-botox-demand-rebounds-2021-07-30 | null | null | July 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N raised its full-year adjusted profit forecast on Friday, as demand soared for its Botox anti-wrinkle injection in the second quarter following the easing of COVID-19 restrictions.
Sales of Botox for cosmetic use rose two-fold to $584 million in the quarter, outpacing esti... | July 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N raised its full-year adjusted profit forecast on Friday, as demand soared for its Botox anti-wrinkle injection in the second quarter following the easing of COVID-19 restrictions. AbbVie has also been focused on expanding the use of plaque psoriasis drug Skryizi and rheum... | July 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N raised its full-year adjusted profit forecast on Friday, as demand soared for its Botox anti-wrinkle injection in the second quarter following the easing of COVID-19 restrictions. AbbVie has also been focused on expanding the use of plaque psoriasis drug Skryizi and rheum... | July 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N raised its full-year adjusted profit forecast on Friday, as demand soared for its Botox anti-wrinkle injection in the second quarter following the easing of COVID-19 restrictions. AbbVie has also been focused on expanding the use of plaque psoriasis drug Skryizi and rheum... | AbbVie said it expects full-year adjusted earnings between $12.52 and $12.62 per share, compared with its previous forecast of $12.37 to $12.57 per share. July 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N raised its full-year adjusted profit forecast on Friday, as demand soared for its Botox anti-wrinkle injection in the... |
23,989 | 2021-07-30 00:00:00 UTC | AbbVie Q2 adjusted earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q2-adjusted-earnings-beat-estimates-2021-07-30 | null | null | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV):
-Earnings: $766 million in Q2 vs. -$738 million in the same period last year. -EPS: $0.42 in Q2 vs. -$0.46 in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $5.55 billion or $3.11 per share for the period. -Analysts proj... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $766 million in Q2 vs. -$738 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $5.55 billion or $3.11 per share for the period. -Guidance: Full year EPS guidance: $12.52 - $12.62 The views and opinions... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $766 million in Q2 vs. -$738 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $5.55 billion or $3.11 per share for the period. -Analysts projected $3.09 per share -Revenue: $13.96 billion in Q2 vs. $1... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $766 million in Q2 vs. -$738 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $5.55 billion or $3.11 per share for the period. -Analysts projected $3.09 per share -Revenue: $13.96 billion in Q2 vs. $1... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $766 million in Q2 vs. -$738 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $5.55 billion or $3.11 per share for the period. -Guidance: Full year EPS guidance: $12.52 - $12.62 The views and opinions... |
23,990 | 2021-07-30 00:00:00 UTC | AbbVie Lifts FY Adj. Profit View | ABBV | https://www.nasdaq.com/articles/abbvie-lifts-fy-adj.-profit-view-2021-07-30 | null | null | (RTTNews) - AbbVie (ABBV) raised its adjusted earnings per share outlook for the full-year 2021 to a range of $12.52 - $12.62 from the prior outlook of $12.37 to $12.57 per share. Analysts polled by Thomson Reuters expect the company to report earnings of $12.6 per share for fiscal year 2021. Analysts' estimates typica... | (RTTNews) - AbbVie (ABBV) raised its adjusted earnings per share outlook for the full-year 2021 to a range of $12.52 - $12.62 from the prior outlook of $12.37 to $12.57 per share. AbbVie cut its annual GAAP earnings per share guidance to a range of $6.04 - $6.14 from the prior outlook of $7.27 - $7.47 per share. Analys... | (RTTNews) - AbbVie (ABBV) raised its adjusted earnings per share outlook for the full-year 2021 to a range of $12.52 - $12.62 from the prior outlook of $12.37 to $12.57 per share. AbbVie cut its annual GAAP earnings per share guidance to a range of $6.04 - $6.14 from the prior outlook of $7.27 - $7.47 per share. The co... | (RTTNews) - AbbVie (ABBV) raised its adjusted earnings per share outlook for the full-year 2021 to a range of $12.52 - $12.62 from the prior outlook of $12.37 to $12.57 per share. AbbVie cut its annual GAAP earnings per share guidance to a range of $6.04 - $6.14 from the prior outlook of $7.27 - $7.47 per share. The co... | (RTTNews) - AbbVie (ABBV) raised its adjusted earnings per share outlook for the full-year 2021 to a range of $12.52 - $12.62 from the prior outlook of $12.37 to $12.57 per share. AbbVie cut its annual GAAP earnings per share guidance to a range of $6.04 - $6.14 from the prior outlook of $7.27 - $7.47 per share. Analys... |
23,991 | 2021-07-29 00:00:00 UTC | Pre-Market Earnings Report for July 30, 2021 : PG, XOM, ABBV, CVX, LIN, CHTR, CAT, ENB, ITW, CL, IDXX, AON | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-july-30-2021-%3A-pg-xom-abbv-cvx-lin-chtr-cat-enb-itw-cl-idxx | null | null | The following companies are expected to report earnings prior to market open on 07/30/2021. Visit our Earnings Calendar for a full list of expected earnings releases.
Procter & Gamble Company (PG)is reporting for the quarter ending June 30, 2021. The cleaning company's consensus earnings per share forecast from the 6 ... | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2021. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 9.39 vs. an industry ratio of 16.20. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2021. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 9.39 vs. an industry ratio of 16.20. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2021. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 9.39 vs. an industry ratio of 16.20. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2021. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 9.39 vs. an industry ratio of 16.20. |
23,992 | 2021-07-29 00:00:00 UTC | How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market | ABBV | https://www.nasdaq.com/articles/how-abbvie-could-make-an-entry-into-this-rapidly-growing-drug-market-2021-07-29 | null | null | Large-cap biopharmaceuticals AbbVie (NYSE: ABBV) and Roche (OTC: RHHBY) announced last week that the U.S. Food and Drug Administration (FDA) had granted their joint effort, Venclexta, a breakthrough therapy designation in combination with an existing chemotherapy, azacitidine, for the treatment of higher-risk myelodysp... | Large-cap biopharmaceuticals AbbVie (NYSE: ABBV) and Roche (OTC: RHHBY) announced last week that the U.S. Food and Drug Administration (FDA) had granted their joint effort, Venclexta, a breakthrough therapy designation in combination with an existing chemotherapy, azacitidine, for the treatment of higher-risk myelodysp... | Large-cap biopharmaceuticals AbbVie (NYSE: ABBV) and Roche (OTC: RHHBY) announced last week that the U.S. Food and Drug Administration (FDA) had granted their joint effort, Venclexta, a breakthrough therapy designation in combination with an existing chemotherapy, azacitidine, for the treatment of higher-risk myelodysp... | Provided that Venclexta's MDS phase 3 study results bear out the data from the phase 1b study as AbbVie is predicting, the company could be setting itself up to penetrate a multibillion-dollar -- and growing -- MDS market. Large-cap biopharmaceuticals AbbVie (NYSE: ABBV) and Roche (OTC: RHHBY) announced last week that ... | Among the 78 adults who were enrolled in the phase 1b study, "65% of patients who were dependent on red blood cell or platelet transfusions were able to achieve independence," according to AbbVie, the study's sponsor. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Kody Kester owns shares of AbbVie and John... |
23,993 | 2021-07-29 00:00:00 UTC | This Biotech Stock Is Too Cheap to Ignore | ABBV | https://www.nasdaq.com/articles/this-biotech-stock-is-too-cheap-to-ignore-2021-07-29 | null | null | Investing in a small biotech company can be maddening. The stock can rise and fall with no news, leaving shareholders wondering who knows something they don't. Over the long term, it's best to stick with the science and ignore the short-term gyrations. But that can be hard.
Trillium Therapeutics (NASDAQ: TRIL) rose 6,0... | Abbvie did follow-up in September by purchasing I-Mab's assets for $200 million. Roughly one-third of patients who had received several prior treatments ended up in complete or partial remission. The results hint at the molecule's ability to penetrate solid tumors, one of the most difficult forms of cancer to treat. | Abbvie did follow-up in September by purchasing I-Mab's assets for $200 million. Trillium Therapeutics (NASDAQ: TRIL) rose 6,000% between December 2019 and November 2020. The drugmaker just dosed its first patient in a phase 2 study and announced positive phase 1 data earlier this month. | Abbvie did follow-up in September by purchasing I-Mab's assets for $200 million. Those drugs, TTI-621 and TTI-622, block the protein CD47, which is a "don't eat me" signal that cancer uses to hide from the immune system. Despite that gap, ALX hasn't demonstrated results as a monotherapy -- without combining it with oth... | Abbvie did follow-up in September by purchasing I-Mab's assets for $200 million. Over 200 patients have been treated with TTI-621. ALX sports a $2.3 billion market cap, compared to only $700 million for Trillium. |
23,994 | 2021-07-29 00:00:00 UTC | AbbVie : FDA Oks Expanded BOTOX Label To Include Eight New Muscles To Treat Upper Limb Spasticity | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-fda-oks-expanded-botox-label-to-include-eight-new-muscles-to-treat-upper-limb | null | null | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration has approved a label expansion of BOTOX to include eight new muscles for the treatment of upper limb spasticity in adults.
The new muscles for treatment include additional muscles of the elbow and forearm, as well as intrins... | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration has approved a label expansion of BOTOX to include eight new muscles for the treatment of upper limb spasticity in adults. BOTOX has been proven to significantly reduce muscle stiffness and is indicated for the treatment of ... | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration has approved a label expansion of BOTOX to include eight new muscles for the treatment of upper limb spasticity in adults. The new muscles for treatment include additional muscles of the elbow and forearm, as well as intrins... | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration has approved a label expansion of BOTOX to include eight new muscles for the treatment of upper limb spasticity in adults. The new muscles for treatment include additional muscles of the elbow and forearm, as well as intrins... | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration has approved a label expansion of BOTOX to include eight new muscles for the treatment of upper limb spasticity in adults. The new muscles for treatment include additional muscles of the elbow and forearm, as well as intrins... |
23,995 | 2021-07-29 00:00:00 UTC | Market Crash 2.0: Where to Invest $1,000 | ABBV | https://www.nasdaq.com/articles/market-crash-2.0%3A-where-to-invest-%241000-2021-07-29 | null | null | Despite reopenings in many parts of the country, we aren't out of the woods with the coronavirus just yet. With the delta variant of the SARS-CoV-2 virus that causes COVID-19 spreading like wildfire, many fear this dreaded pandemic may extend well beyond 2021. These concerns fueled a terrible, horrible, no-good, very b... | AbbVie's current lineup will make up for Humira's eventual decline, and the company's robust pipeline will also contribute to beefing up its portfolio of medicines. Patients need drugs, particularly life-saving ones, regardless of economic conditions, and that's why AbbVie is well-positioned to navigate a potential dow... | AbbVie Pharma giant AbbVie will likely start facing competition from biosimilars in the U.S. for Humira, its best-selling drug, in 2023. Two companies that would be great options in case of another market downturn are AbbVie (NYSE: ABBV) and Netflix (NASDAQ: NFLX). But AbbVie's management team foresaw this situation an... | Patients need drugs, particularly life-saving ones, regardless of economic conditions, and that's why AbbVie is well-positioned to navigate a potential downturn -- and why it'd be a good idea to scoop up shares of this pharma stock in case of a market crash. Two companies that would be great options in case of another ... | AbbVie Pharma giant AbbVie will likely start facing competition from biosimilars in the U.S. for Humira, its best-selling drug, in 2023. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! Two companies that would be great options in case of an... |
23,996 | 2021-07-28 00:00:00 UTC | Here's Why Myovant Sciences Stock Is Falling Today | ABBV | https://www.nasdaq.com/articles/heres-why-myovant-sciences-stock-is-falling-today-2021-07-28 | null | null | What happened
Myovant Sciences (NYSE: MYOV) stock is losing ground after the company reported earnings for its fiscal first quarter, the three-month period ended June 30, 2021. Investors upset about net product sales that weren't very impressive led the stock 12.5% lower this morning. The stock recovered some losses an... | Back in 2018, AbbVie (NYSE: ABBV) launched its own oral GnRH inhibitor called Orilissa to relieve pain associated with endometriosis. AbbVie's challenges with its GnRH inhibitor don't necessarily need to carry over to Myovant and Pfizer's launch of Myfembree. What happened Myovant Sciences (NYSE: MYOV) stock is losing ... | Back in 2018, AbbVie (NYSE: ABBV) launched its own oral GnRH inhibitor called Orilissa to relieve pain associated with endometriosis. AbbVie's challenges with its GnRH inhibitor don't necessarily need to carry over to Myovant and Pfizer's launch of Myfembree. So what Sales of products containing Myovant's gonadotropin-... | Back in 2018, AbbVie (NYSE: ABBV) launched its own oral GnRH inhibitor called Orilissa to relieve pain associated with endometriosis. AbbVie's challenges with its GnRH inhibitor don't necessarily need to carry over to Myovant and Pfizer's launch of Myfembree. What happened Myovant Sciences (NYSE: MYOV) stock is losing ... | Back in 2018, AbbVie (NYSE: ABBV) launched its own oral GnRH inhibitor called Orilissa to relieve pain associated with endometriosis. AbbVie's challenges with its GnRH inhibitor don't necessarily need to carry over to Myovant and Pfizer's launch of Myfembree. So what Sales of products containing Myovant's gonadotropin-... |
23,997 | 2021-07-28 00:00:00 UTC | Thinking About Joining the Dogecoin Craze? Here are 2 Smarter Buys | ABBV | https://www.nasdaq.com/articles/thinking-about-joining-the-dogecoin-craze-here-are-2-smarter-buys-2021-07-28 | null | null | The cryptocurrency market continues to be fraught with extreme volatility. Dogecoin -- a digital currency favored by Reddit traders that was initially started as a joke eight years ago -- is certainly no exception. The crypto's up by more than 5,600% from just one year ago but has fallen nearly 40% in value over the pa... | While biosimilar competition is sure to put a dent in sales of Humira once its U.S. patent exclusivity ends, the drug is likely to continue generating substantial balance-sheet growth for AbbVie. AbbVie Healthcare stock AbbVie (NYSE:ABBV) is another compelling buy for long-term investors. Prospective buyers should know... | AbbVie Healthcare stock AbbVie (NYSE:ABBV) is another compelling buy for long-term investors. Prospective buyers should know that AbbVie is a member of the elite club of stocks called Dividend Aristocrats. In fact, AbbVie is just shy of being crowned a Dividend King. | AbbVie Healthcare stock AbbVie (NYSE:ABBV) is another compelling buy for long-term investors. Prospective buyers should know that AbbVie is a member of the elite club of stocks called Dividend Aristocrats. In fact, AbbVie is just shy of being crowned a Dividend King. | AbbVie Healthcare stock AbbVie (NYSE:ABBV) is another compelling buy for long-term investors. Prospective buyers should know that AbbVie is a member of the elite club of stocks called Dividend Aristocrats. In fact, AbbVie is just shy of being crowned a Dividend King. |
23,998 | 2021-07-27 00:00:00 UTC | AbbVie, Calico Again Extend Collaboration Focused On Aging And Age-Related Diseases | ABBV | https://www.nasdaq.com/articles/abbvie-calico-again-extend-collaboration-focused-on-aging-and-age-related-diseases-2021-07 | null | null | (RTTNews) - AbbVie (ABBV) and Calico Life Sciences agreed to extend their collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. It is the second extension of the collaboration originally established in 2014.
As part of the co... | (RTTNews) - AbbVie (ABBV) and Calico Life Sciences agreed to extend their collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. As part of the collaboration, working together with AbbVie, Calico pursues discovery-stage resear... | As part of the collaboration, working together with AbbVie, Calico pursues discovery-stage research and development utilizing state-of-the-art technology and advanced computing capabilities. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the opti... | (RTTNews) - AbbVie (ABBV) and Calico Life Sciences agreed to extend their collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. As part of the collaboration, working together with AbbVie, Calico pursues discovery-stage resear... | AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities. (RTTNews) - AbbVie (ABBV) and Calico Life Sciences agreed to extend their collaboration to discover, develop and bring to market... |
23,999 | 2021-07-26 00:00:00 UTC | The Smartest Dividend Aristocrats to Buy With $500 Right Now | ABBV | https://www.nasdaq.com/articles/the-smartest-dividend-aristocrats-to-buy-with-%24500-right-now-2021-07-26 | null | null | Aristocracy isn't all it's cracked up to be. You'd think that stocks that are Dividend Aristocrats -- members of the S&P 500 with at least 25 consecutive years of dividend increases -- would by default have really attractive dividends. Many of them don't. And quite a few of those with relatively puny dividend yields ha... | AbbVie You won't find too many stocks that offer a more attractive dividend than AbbVie (NYSE: ABBV). AbbVie is a spin-off from another Dividend Aristocrat, Abbott Labs. Since the two companies separated in 2013, AbbVie has increased its dividend by a whopping 225%. | AbbVie You won't find too many stocks that offer a more attractive dividend than AbbVie (NYSE: ABBV). AbbVie is a spin-off from another Dividend Aristocrat, Abbott Labs. Since the two companies separated in 2013, AbbVie has increased its dividend by a whopping 225%. | AbbVie You won't find too many stocks that offer a more attractive dividend than AbbVie (NYSE: ABBV). AbbVie is a spin-off from another Dividend Aristocrat, Abbott Labs. Since the two companies separated in 2013, AbbVie has increased its dividend by a whopping 225%. | AbbVie You won't find too many stocks that offer a more attractive dividend than AbbVie (NYSE: ABBV). AbbVie is a spin-off from another Dividend Aristocrat, Abbott Labs. Since the two companies separated in 2013, AbbVie has increased its dividend by a whopping 225%. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.